Podcasts about informing

Today we're talking with health and nutrition expert Dr. Stuart Gillespie, author of a new book entitled Food Fight: from Plunder and Profit to People and Planet. Using decades of research and insight gathered from around the world, Dr. Gillespie wants to reimagine our global food system and plot a way forward to a sustainable, equitable, and healthy food future - one where our food system isn't making us sick. Certainly not the case now. Over the course of his career, Dr. Gillespie has worked with the UN Standing Committee on Nutrition in Geneva with UNICEF in India and with the International Food Policy Research Institute, known as IFPRI, where he's led initiatives tackling the double burden of malnutrition and agriculture and health research. He holds a PhD in human nutrition from the London School of Hygiene and Tropical Medicine. Interview Summary So, you've really had a global view of the agriculture system, and this is captured in your book. And to give some context to our listeners, in your book, you describe the history of the global food system, how it's evolved into this system, sort of warped, if you will, into a mechanism that creates harm and it destroys more than it produces. That's a pretty bold statement. That it destroys more than it produces, given how much the agriculture around the world does produce. Tell us a bit more if you would. Yes, that statement actually emerged from recent work by the Food Systems Economic Commission. And they costed out the damage or the downstream harms generated by the global food system at around $15 trillion per year, which is 12% of GDP. And that manifests in various ways. Health harms or chronic disease. It also manifests in terms of climate crisis and risks and environmental harms, but also. Poverty of food system workers at the front line, if you like. And it's largely because we have a system that's anachronistic. It's a system that was built in a different time, in a different century for a different purpose. It was really started to come together after the second World War. To mass produce cheap calories to prevent famine, but also through the Green Revolution, as that was picking up with the overproduction of staples to use that strategically through food aid to buffer the West to certain extent from the spread of communism. And over time and over the last 50 years of neoliberal policies we've got a situation where food is less and less viewed as a human right, or a basic need. It's seen as a commodity and the system has become increasingly financialized. And there's a lot of evidence captured by a handful of transnationals, different ones at different points in the system from production to consumption. But in each case, they wield huge amounts of power. And that manifests in various ways. We have, I think a system that's anachronistic The point about it, and the problem we have, is that it's a system revolves around maximizing profit and the most profitable foods and products of those, which are actually the least healthy for us as individuals. And it's not a system that's designed to nourish us. It's a system designed to maximize profit. And we don't have a system that really aims to produce whole foods for people. We have a system that produces raw ingredients for industrial formulations to end up as ultra processed foods. We have a system that produces cattle feed and, and biofuels, and some whole foods. But it, you know, that it's so skewed now, and we see the evidence all around us that it manifests in all sorts of different ways. One in three people on the planet in some way malnourished. We have around 12 million adult deaths a year due to diet related chronic disease. And I followed that from colonial times that, that evolution and the way it operates and the way it moves across the world. And what is especially frightening, I think, is the speed at which this so-called nutrition transition or dietary transition is happening in lower income or middle income countries. We saw this happening over in the US and we saw it happening in the UK where I am. And then in Latin America, and then more Southeast Asia, then South Asia. Now, very much so in Sub-Saharan Africa where there is no regulation really, apart from perhaps South Africa. So that's long answer to your intro question. Let's dive into a couple of things that you brought up. First, the Green Revolution. So that's a term that many of our listeners will know and they'll understand what the Green Revolution is, but not everybody. Would you explain what that was and how it's had these effects throughout the food systems around the world? Yes, I mean around the, let's see, about 1950s, Norman Borlag, who was a crop breeder and his colleagues in Mexico discovered through crop breeding trials, a high yielding dwarf variety. But over time and working with different partners, including well in India as well, with the Swaminathan Foundation. And Swaminathan, for example, managed to perfect these new strains. High yielding varieties that doubled yields for a given acreage of land in terms of staples. And over time, this started to work with rice, with wheat, maize and corn. Very dependent on fertilizers, very dependent on pesticides, herbicides, which we now realize had significant downstream effects in terms of environmental harms. But also, diminishing returns in as much as, you know, that went through its trajectory in terms of maximizing productivity. So, all the Malthusian predictions of population growth out running our ability to feed the planet were shown to not to be true. But it also generated inequity that the richest farmers got very rich, very quickly, the poorer farmers got slightly richer, but that there was this large gap. So, inequity was never really properly dealt with through the Green Revolution in its early days. And that overproduction and the various institutions that were set in place, the manner in which governments backed off any form of regulation for overproduction. They continued to subsidize over production with these very large subsidies upstream, meant that we are in the situation we are now with regard to different products are being used to deal with that excess over production. So, that idea of using petroleum-based inputs to create the foods in the first place. And the large production of single crops has a lot to do with that Green Revolution that goes way back to the 1950s. It's interesting to see what it's become today. It's sort of that original vision multiplied by a billion. And boy, it really does continue to have impacts. You know, it probably was the forerunner to genetically modified foods as well, which I'd like to ask you about in a little bit. But before I do that, you said that much of the world's food supply is governed by a pretty small number of players. So who are these players? If you look at the downstream retail side, you have Nestle, PepsiCo, Coca-Cola, General Mills, Unilever. Collectively around 70% of retail is governed by those companies. If you look upstream in terms of agricultural and agribusiness, you have Cargill, ADM, Louis Dreyfus, and Bunge. These change to a certain extent. What doesn't change very much are the numbers involved that are very, very small and that the size of these corporations is so large that they have immense power. And, so those are the companies that we could talk about what that power looks like and why it's problematic. But the other side of it's here where I am in the UK, we have a similar thing playing out with regard to store bought. Food or products, supermarkets that control 80% as Tesco in the UK, Asta, Sainsbury's, and Morrisons just control. You have Walmart, you have others, and that gives them immense power to drive down the costs that they will pay to producers and also potentially increase the cost that they charge as prices of the products that are sold in these supermarkets. So that profit markup, profit margins are in increased in their favor. They can also move around their tax liabilities around the world because they're transnational. And that's just the economic market and financial side on top of that. And as you know, there's a whole raft of political ways in which they use this power to infiltrate policy, influence policy through what I've called in Chapter 13, the Dark Arts of Policy Interference. Your previous speaker, Murray Carpenter, talked about that with regard to Coca-Cola and that was a very, yeah, great example. But there are many others. In many ways these companies have been brilliant at adapting to the regulatory landscape, to the financial incentives, to the way the agriculture system has become warped. I mean, in some ways they've done the warping, but in a lot of ways, they're adapting to the conditions that allow warping to occur. And because they've invested so heavily, like in manufacturing plants to make high fructose corn syrup or to make biofuels or things like that. It'd be pretty hard for them to undo things, and that's why they lobby so strongly in favor of keeping the status quo. Let me ask you about the issue of power because you write about this in a very compelling way. And you talk about power imbalances in the food system. What does that look like in your mind, and why is it such a big part of the problem? Well, yes. And power manifests in different ways. It operates sometimes covertly, sometimes overtly. It manifests at different levels from, you know, grassroots level, right up to national and international in terms of international trade. But what I've described is the way markets are captured or hyper concentrated. That power that comes with these companies operating almost like a cartel, can be used to affect political or to dampen down, block governments from regulating them through what I call a five deadly Ds: dispute or dispute or doubt, distort, distract, disguise, and dodge. And you've written very well Kelly, with I think Kenneth Warner about the links between big food and big tobacco and the playbook and the realization on the part of Big Tobacco back in the '50s, I think, that they couldn't compete with the emerging evidence of the harms of smoking. They had to secure the science. And that involved effectively buying research or paying for researchers to generate a raft of study shown that smoking wasn't a big deal or problem. And also, public relations committees, et cetera, et cetera. And we see the same happening with big food. Conflicts of interest is a big deal. It needs to be avoided. It can't be managed. And I think a lot of people think it is just a question of disclosure. Disclosure is never enough of conflict of interest, almost never enough. We have, in the UK, we have nine regulatory bodies. Every one of them has been significantly infiltrated by big food, including the most recent one, which has just been designated to help develop a national food stretch in the UK. We've had a new government here and we thought things were changing, beginning to wonder now because big food is on that board or on that committee. And it shouldn't be, you know. It shouldn't be anywhere near the policy table anyway. That's so it's one side is conflict of interest. Distraction: I talk about corporate social responsibility initiatives and the way that they're designed to distract. On the one hand, if you think of a person on a left hand is doing these wonderful small-scale projects, which are high visibility and they're doing good. In and off themselves they're doing good. But they're small scale. Whereas the right hand is a core business, which is generating harm at a much larger scale. And the left hand is designed to distract you from the right hand. So that distraction, those sort of corporate CSR initiatives are a big part of the problem. And then 'Disguise' is, as you know, with the various trade associations and front groups, which acted almost like Trojan horses, in many ways. Because the big food companies are paying up as members of these committees, but they don't get on the program of these international conferences. But the front groups do and the front groups act on in their interests. So that's former disguise or camouflage. The World Business Council on Sustainable Development is in the last few years, has been very active in the space. And they have Philip Morris on there as members, McDonald's and Nestle, Coke, everybody, you know. And they deliberately actually say It's all fine. That we have an open door, which I, I just can't. I don't buy it. And there are others. So, you know, I think these can be really problematic. The other thing I should mention about power and as what we've learned more about, if you go even upstream from the big food companies, and you look at the hedge funds and the asset management firms like Vanguard, state Capital, BlackRock, and the way they've been buying up shares of big food companies and blocking any moves in annual general meetings to increase or improve the healthiness of portfolios. Because they're so powerful in terms of the number of shares they hold to maximize profit for pension funds. So, we started to see the pressure that is being put on big food upstream by the nature of the system, that being financialized, even beyond the companies themselves, you know? You were mentioning that these companies, either directly themselves or through their front organizations or the trade association block important things that might be done in agriculture. Can you think of an example of that? Yes, well actually I did, with some colleagues here in the UK, the Food Foundation, an investigation into corporate lobbying during the previous conservative government. And basically, in the five years after the pandemic, we logged around 1,400 meetings between government ministers and big food. Then we looked at the public interest NGOs and the number of meetings they had over that same period, and it was 35, so it was a 40-fold difference. Oh goodness. Which I was actually surprised because I thought they didn't have to do much because the Tory government was never going to really regulate them anyway. And you look in the register, there is meant to be transparency. There are rules about disclosure of what these lobbying meetings were meant to be for, with whom, for what purpose, what outcome. That's just simply not followed. You get these crazy things being written into the those logs like, 'oh, we had a meeting to discuss business, and that's it.' And we know that at least what happened in the UK, which I'm more familiar with. We had a situation where constantly any small piecemeal attempt to regulate, for example, having a watershed at 9:00 PM so that kids could not see junk food advertised on their screens before 9:00 PM. That simple regulation was delayed, delayed. So, delay is actually another D you know. It is part of it. And that's an example of that. That's a really good example. And you've reminded me of an example where Marian Nestle and I wrote an op-ed piece in the New York Times, many years ago, on an effort by the WHO, the World Health Organization to establish a quite reasonable guideline for how much added sugar people should have in their diet. And the sugar industry stepped in in the biggest way possible. And there was a congressional caucus on sugar or something like that in our US Congress and the sugar industry and the other players in the food industry started interacting with them. They put big pressure on the highest levels of the US government to pressure the WHO away from this really quite moderate reasonable sugar standard. And the US ultimately threatened the World Health Organization with taking away its funding just on one thing - sugar. Now, thankfully the WHO didn't back down and ultimately came out with some pretty good guidelines on sugar that have been even stronger over the years. But it was pretty disgraceful. That's in the book that, that story is in the book. I think it was 2004 with the strategy on diet, physical activity. And Tommy Thompson was a health secretary and there were all sorts of shenanigans and stories around that. Yes, that is a very powerful example. It was a crazy power play and disgraceful how our government acted and how the companies acted and all the sort of deceitful ways they did things. And of course, that's happened a million times. And you gave the example of all the discussions in the UK between the food industry and the government people. So, let's get on to something more positive. What can be done? You can see these massive corporate influences, revolving doors in government, a lot of things that would argue for keeping the status quo. So how in the world do you turn things around? Yeah, good question. I really believe, I've talked about a lot of people. I've looked a lot of the evidence. I really believe that we need a systemic sort of structural change and understanding that's not going to happen overnight. But ultimately, I think there's a role for a government, citizens civil society, media, academics, food industry, obviously. And again, it's different between the UK and US and elsewhere in terms of the ability and the potential for change. But governments have to step in and govern. They have to set the guardrails and the parameters. And I talk in the book about four key INs. So, the first one is institutions in which, for example, there's a power to procure healthy food for schools, for hospitals, clinics that is being underutilized. And there's some great stories of individuals. One woman from Kenya who did this on her own and managed to get the government to back it and to scale it up, which is an incredible story. That's institutions. The second IN is incentives, and that's whereby sugar taxes, or even potentially junk food taxes as they have in Columbia now. And reforming the upstream subsidies on production is basically downregulating the harmful side, if you like, of the food system, but also using the potential tax dividend from that side to upregulate benefits via subsidies for low-income families. Rebalancing the system. That's the incentive side. The other side is information, and that involves labeling, maybe following the examples from Latin America with regard to black octagons in Chile and Mexico and Brazil. And dietary guidelines not being conflicted, in terms of conflicts of interest. And actually, that's the fourth IN: interests. So ridding government advisory bodies, guideline committees, of conflicts of interests. Cleaning up lobbying. Great examples in a way that can be done are from Canada and Ireland that we found. That's government. Citizens, and civil society, they can be involved in various ways exposing, opposing malpractice if you like, or harmful action on the part of industry or whoever else, or the non-action on the part of the government. Informing, advocating, building social movements. Lots I think can be learned through activist group in other domains or in other disciplines like HIV, climate. I think we need to make those connections much more. Media. I mean, the other thought is that the media have great, I mean in this country at least, you know, politicians tend to follow the media, or they're frightened of the media. And if the media turned and started doing deep dive stories of corporate shenanigans and you know, stuff that is under the radar, that would make a difference, I think. And then ultimately, I think then our industry starts to respond to different signals or should do or would do. So that in innovation is not just purely technological aimed at maximizing profit. It may be actually social. We need social innovation as well. There's a handful of things. But ultimately, I actually don't think the food system is broken because it is doing the wrong thing for the wrong reason. I think we need to change the system, and I'll say that will take time. It needs a real transformation. One, one last thing to say about that word transformation. Where in meetings I've been in over the last 10 years, so many people invoke food system transformation when they're not really talking about it. They're just talking about tweaking the margins or small, piecemeal ad hoc changes or interventions when we need to kind of press all the buttons or pull all the levers to get the kind of change that we need. And again, as I say, it was going to take some time, but we have to start moving that direction. Do you think there's reason to be hopeful and are there success stories you can point to, to make us feel a little bit better? Yeah, and I like that word, hope. I've just been reading a lot of essays from, actually, Rebecca Solnit has been writing a lot about hope as a warrior emotion. Radical hope, which it's different to optimism. Optimism went, oh, you know, things probably will be okay, but hope you make it. It's like a springboard for action. So I, yes, I'm hopeful and I think there are plenty of examples. Actually, a lot of examples from Latin America of things changing, and I think that's because they've been hit so fast, so hard. And I write in the book about what's happened in the US and UK it's happened over a period of, I don't know, 50, 60 years. But what's happened and is happening in Latin America has happened in just like 15 years. You know, it's so rapid that they've had to respond fast or get their act together quickly. And that's an interesting breed of activist scholars. You know, I think there's an interesting group, and again, if we connect across national boundaries across the world, we can learn a lot from that. There are great success stories coming out Chile from the past that we've seen what's happening in Mexico. Mexico was in a terrible situation after Vicente Fox came in, in the early 2000s when he brought all his Coca-Cola pals in, you know, the classic revolving door. And Mexico's obesity and diabetes went off to scale very quickly. But they're the first country with the sugar tax in 2014. And you see the pressure that was used to build the momentum behind that. Chile, Guido Girardi and the Black Octagon labels with other interventions. Rarely is it just one thing. It has to be a comprehensive across the board as far as possible. So, in Brazil, I think we will see things happening more in, in Thailand and Southeast Asia. We see things beginning to happen in India, South Africa. The obesity in Ghana, for example, changed so rapidly. There are some good people working in Ghana. So, you know, I think a good part of this is actually documenting those kind of stories as, and when they happen and publicizing them, you know. The way you portrayed the concept of hope, I think is a really good one. And when I asked you for some examples of success, what I was expecting you, you might say, well, there was this program and this part of a one country in Africa where they did something. But you're talking about entire countries making changes like Chile and Brazil and Mexico. That makes me very hopeful about the future when you get governments casting aside the influence of industry. At least long enough to enact some of these things that are definitely not in the best interest of industry, these traditional food companies. And that's all, I think, a very positive sign about big scale change. And hopefully what happens in these countries will become contagious in other countries will adopt them and then, you know, eventually they'll find their way to countries like yours and mine. Yes, I agree. That's how I see it. I used to do a lot of work on single, small interventions and do their work do they not work in this small environment. The problem we have is large scale, so we have to be large scale as well. BIO Dr. Stuart Gillespie has been fighting to transform our broken food system for the past 40 years. Stuart is a Non-Resident Senior Fellow in Nutrition, Diets and Health at theInternational Food Policy Research Institute (IFPRI). He has been at the helm of the IFPRI's Regional Network on AIDs, Livelihoods and Food Security, has led the flagship Agriculture for Nutrition and Health research program, was director of the Transform Nutrition program, and founded the Stories of Change initiative, amongst a host of other interventions into public food policy. His work – the ‘food fight' he has been waging – has driven change across all frontiers, from the grassroots (mothers in markets, village revolutionaries) to the political (corporate behemoths, governance). He holds a PhD in Human Nutrition from the London School of Hygiene and Tropical Medicine. 

Title: Schemers, Sharks, and A Snitch Text: Acts 23:12-35 FCF: We often struggle trusting God when enemies surround us. Prop: Because man makes their plans but God guides their steps, we must trust the Lord. Scripture Intro: [Slide 1] Turn in your bible to Acts chapter 23. In a moment we'll begin reading from the LSB starting in verse 12. You can follow along in the pew bible or whatever version you prefer. After Paul narrowly escapes the clutches of the Sanhedrin, Jesus comes to him in the night and comforts him. He tells Paul to have courage because just as he has declared the gospel in Jerusalem he must also go to Rome and do the same. But we are still two and a half years away from Jesus' promise being fulfilled. In the remaining 5 and a half chapters of this book, we will see God's hand of providence working to have His apostle arrive in Rome at precisely the right time for him to be there. An apostle of God is never early, nor is he late, but arrives precisely when God needs him to. And that all begins with the episode today. Because of the events recorded in today's text, Paul's trip to Rome will be put on God's time table. So, let's stand to give honor to and to focus on the reading of the Word of God. Invocation: Sovereign Lord, You know the plans of the wicked. You have seen their devices and You know their hearts. You have measured the pride of men vying for power while they use others to get it. In a world that seems to be spiraling out of control, where the wicked prosper and the righteous fall, You have your eye even on the sparrows. Not one of them falls down dead without Your knowledge and You have ordered all things for the good of Your people – who are far more valuable than the birds. The Son has given us infinite worth by sending the Comforter to indwell us. Father use Your Spirit to give to us insight into Your word today to see Your good plan for Your children … even amid and through the plotting and power grabbing of ungodly men. Open our eyes today we pray in Jesus' name. Amen. Transition: Proverbs 16 kept flitting through my mind as I studied this passage. Let me read that to you now, by way of an introduction, even before we dive into the text of Acts 23. The plans of the heart belong to man, But the answer of the tongue is from Yahweh. 2 All the ways of a man are pure in his own sight, But Yahweh weighs the motives. 3 Commit your works to Yahweh And your plans will be established. 4 Yahweh has made everything for its own purpose, Even the wicked for the day of evil. 5 Everyone who is proud in heart is an abomination to Yahweh; Assuredly, he will not be unpunished. 6 By lovingkindness and truth iniquity is atoned for, And by the fear of Yahweh one turns away from evil. 7 When a man's ways are pleasing to Yahweh, He makes even his enemies to be at peace with him. 8 Better is a little with righteousness Than great produce with injustice. 9 The heart of man plans his way, But Yahweh directs his steps. With these words in mind, look with me at verse 12. I.) Mankind makes their wicked plans in secret, but we must trust the Lord. (12-15) a. [Slide 2] 12 - Now when it was day, the Jews formed a conspiracy and bound themselves under a curse, saying that they would neither eat nor drink until they had killed Paul. 13 - And there were more than forty who formed this scheme. i. Right on the heels of Paul being rescued out of the hands of the Jews… AGAIN… we find that the very next day he is right back in the fire. ii. The first scene of this episode opens with a group of 40 Jews who come up with a plan to do something especially vile. iii. Through our study of the gospel of Matthew and the book of Acts, we've seen the first century Jews do a lot of wicked things. Chief among them the betrayal and murder of their own Messiah. iv. Although the events of this text do not compare to the murder of their own God-King, it certainly has a rather sinister stench about it. v. Why is this so wicked? vi. First, we must understand the nature of a curse. 1. The words translated “bound under a curse” is one word. It is the word Anathematize. It means to submit to divine destruction for failure to uphold their end. 2. Even to submit to eternal Divine punishment if they eat or drink anything before they kill Paul. 3. May God cast me in hell if I eat or drink anything before I kill Paul. vii. Secondly, we must understand the foolishness of this curse. 1. First, there are two ways they fail this curse. Either they eat or drink something before they kill Paul, or they never kill Paul and die of starvation. 2. Second, this curse is only succeeded by them committing an act which God expressly forbids in the decalogue… You shall not murder. 3. Particularly heinous in the Mosaic law was someone who premeditated murder. 4. God hates hands that shed innocent blood and a heart that devises wicked schemes. Prov 6:16-19 viii. 40 Jewish men form this wicked plan. But they are not alone… b. [Slide 3] 14 - They came to the chief priests and the elders and said, “We have bound ourselves under a curse to taste nothing until we have killed Paul. 15 - So now you, along with the Sanhedrin, notify the commander to bring him down to you, as though you were going to determine his case more carefully; and we for our part are ready to slay him before he comes near.” i. They inform the chief priests and elders of Israel about the curse they have placed on themselves. ii. If the chief priests and elders were righteous, they would have these men thrown in jail. They would have at least refused to aid them. iii. Instead, they help to facilitate the plan. But what is the plan? iv. To go with the Sanhedrin to the Roman commander and notify him that the Sanhedrin would like a do over on the trial. They want to look more carefully at his case. v. This is, of course, a lie. vi. Add that to the growing list of sins that God hates wrapped up in this plot. vii. The plan then, is that while he is enroute to the Sanhedrin's chambers, these 40 men will accost and kill Paul. viii. Which is a plan that isn't without risk. Paul certainly would have some sort of Roman escort. It is possible that some of them may die or be executed for their hand in this. ix. This is the length to which these Jews will go to kill Paul. c. [Slide 4] Summary of the Point: Luke once again shows us the agency and responsibility of men. These 40 Jews, the chief priests, the elders, the Sanhedrin, all form this conspiracy, these secret plans whispered in empty halls with murder on their lips. God doesn't intervene here. He doesn't snap his fingers and snuff out the breathe of these conspirators. He doesn't prevent them from thinking of these sinful deeds. He doesn't kill them in their sleep. God allows wicked men to be wicked. To make their plans. However much we make of God's absolute Sovereignty we must not cross the threshold as some have in saying that if God doesn't want me to do something, He can stop me from doing it. This is true… but God often doesn't stop men from sinning. Nor can we say that God can't judge me for my actions if He Himself has orchestrated them to accomplish His purposes. Just ask Pharoah about that one. God permits, at very least, the perception of human agency and responsibility to ensure that He is never the first cause of someone sinning. They are. These men are responsible for their wicked deeds. So what must we do in response? We must trust the Lord. God has promised to never leave us, and to preserve us. But that doesn't mean He will not allow men to form and even execute wicked plans against us. Trusting God doesn't mean we'll never experience hardship… it means we trust that God even uses hardship for our good and His glory. Transition: [Slide 5(blank)] The plan has been made and the stage is set. It seems like no one will be able to stop them from killing Paul this time. It looks like Jesus' promise will end up being false. Of course, we know that cannot be true. So how does God frustrate the plans of the wicked? II.) God providentially guides the steps of all men, so we must trust the Lord. (16-35) a. [Slide 6] 16 - But when the son of Paul's sister heard of their ambush, he came and entered the barracks and reported it to Paul. i. Debate abounds on how exactly Paul's nephew heard about this plan. ii. In reality the options are almost endless. Luke doesn't think the details relevant to convey – only the fact that this young man heard of the plot. iii. We also get a rare look at the family of Paul here. iv. It is supposed by many that Paul's family rejected him after he became a Christian. Some even suggest that Paul was probably married and his wife was granted a divorce because of his conversion to Christ. This is all conjecture of course. v. But we do know at least that Paul's nephew, the son of his sister, is living in Jerusalem. If he has also turned his back on Paul it seems odd that he would take an interest in preserving Paul's life. vi. Perhaps catching wind of such a wicked plot turns his heart toward helping Paul. Perhaps he has converted to Christ. Much of this, again, is conjecture and not details that Luke chooses to share. vii. But what does his nephew do? viii. He does the righteous thing and informs Paul immediately. ix. Let this be a lesson to all, informing others of someone's plan to do evil is not narcing or snitching or in some way a betrayal to those doing wicked things. We must be on the side of righteousness not tribalism or even loyalty to other human beings. Let God's kingdom and righteousness be your only loyalty… even if it costs you friends or associates. b. [Slide 7] 17 - And Paul called one of the centurions to him and said, “Lead this young man to the commander, for he has something to report to him.” 18 - So he took him and led him to the commander and said, “Paul the prisoner called me to him and asked me to lead this young man to you since he has something to tell you.” 19 - And the commander took him by the hand and stepping aside, began to inquire of him privately, “What is it that you have to report to me?” 20 - And he said, “The Jews have agreed to ask you to bring Paul down tomorrow to the Sanhedrin, as though they were going to inquire somewhat more carefully about him. 21 - “So do not be persuaded by them, for more than forty of them—who have bound themselves under a curse not to eat or drink until they slay him—are lying in wait for him and now they are ready and waiting for the promise from you.” i. In this rather lengthy section of scripture, not a lot actually transpires in the narrative. ii. Luke establishes the chain of information for us in that Paul calls a centurion to take his young nephew to the Roman commander with an urgent piece of information. iii. Notice that Paul does not tell the centurion what the boy told him. iv. A couple reasons for this. 1. It would probably be more believable coming from the boy than from Paul 2. It keeps fewer people knowing about the plot and the fact that Paul now knows about it. v. So the centurion takes the boy to the commander. vi. The commander takes him to a private place, probably because he understood that the information he was to convey needed to be spoken privately. vii. After this Paul's nephew informs the Roman commander of the scheme of these 40 Jews and the Sanhedrin who have conspired together to kill Paul before he arrived. viii. Again, it is helpful for us to remember that Paul is a prisoner of the Roman Empire. He is probably not in some kind of formal custody. Perhaps simply protective custody. But custody nonetheless. ix. And for the commander to allow a prisoner to be accosted and killed under his watch would have made him look like he wasn't doing his job. x. Thus, we do not have this commander shaking off this information as if it matters little to him. xi. Quite the contrary. c. [Slide 8] 22 - So the commander let the young man go, instructing him, “Tell no one that you have notified me of these things.” 23 - And when he called to him two of the centurions, he said, “Make ready two hundred soldiers, seventy horsemen, and two hundred spearmen to proceed to Caesarea by the third hour of the night, 24 - and provide mounts to put Paul on and bring him safely to Felix the governor.” i. The commander first instructs the young man not to tell ANYONE that he told the commander this. ii. He doesn't want the fact that he knows about this to get back to the schemers. iii. Immediately the Roman Commander makes plans to get Paul out of Jerusalem. iv. If these Jews are going to start plotting and scheming while Rome protects him, then it seems best to get him out of Jerusalem. v. The Commander makes quite the plan to see Paul to safety. vi. He gathers 470 soldiers in total to escort Paul the 60 miles to Caesarea. He does so on the third hour of the night, which would be around 9pm. vii. He also makes sure that Paul rides on a mount and charges the whole company to bring Paul safely to Felix the governor of Judea. viii. But The commander also sends his own account to the governor. ix. In order for a proper transfer of a case and to submit a chain of evidence to that trial, this would probably be a normal practice within the Roman Empire's legal proceedings. x. As such, some questions have arisen as to how Luke could have gotten his hands on this letter. And the fact of the matter is that this letter would have followed Paul all the way to Rome as part of the case notes. And certainly, at some point Paul or Luke would have either heard it presented or gotten to see it himself. xi. Therefore, we don't need to doubt the authenticity of the letter, nor do we need to assume Luke is summarizing what the commander says. He probably heard it read several times, and potentially even was able to make a copy of it himself. d. [Slide 9] 25 - And he wrote a letter having this form: 26 - “Claudius Lysias, to the most excellent governor Felix, greetings. 27 - When this man was arrested by the Jews and was about to be slain by them, I came up to them with the troops and rescued him, having learned that he was a Roman. 28 - And wanting to ascertain the charge for which they were accusing him, I brought him down to their Sanhedrin; 29 - and I found him to be accused over questions about their Law, but under no accusation deserving death or imprisonment. 30 - And when I was informed that there would be a plot against the man, I sent him to you at once, also instructing his accusers to speak against him before you.” i. Here we learn the name of the Roman commander who has been God's agent of rescuing Paul through these various attempts on his life. ii. He identifies himself as Claudius Lysias. A Greek name, indicating to us as we've said before that this man was no doubt from a wealthy Greek family who purchased his future within the Roman Empire. Starting with his citizenship and even his position as a Commander in Judea. iii. He sends his account of all that has happened and his account is very interesting indeed. iv. The first point is a rather self-aggrandizing version of the story Luke told. 1. The Jews did not actually arrest Paul, they were simply beating him and the Lysias stopped it. 2. Furthermore, Lysias makes it seem like he rescued Paul because he had learned that Paul was a Roman citizen. With a little logic and reasoning we could easily determine that this would be quite difficult to do in the midst of the Jews arresting him and trying to kill him. 3. Again, this doesn't quite jive with Luke's version of the story. But we can see why Lysias would want to fudge a few details to get himself out of trouble. 4. To admit that he allowed a riot to break out on the temple mount only a couple flights of stairs from the Anatolian fortress would not be good for him to report to the higher ups. 5. We also see he does not mention how he ACTUALLY found out Paul was a Roman citizen, which was in the midst of binding and almost flogging him. 6. This is as much a political letter as it is a legal document. Lysias is portraying himself as a great hero to try to score some points with his superiors. v. The second point is fairly consistent with what Luke recorded. 1. Lysias did want to determine the real reason he was in trouble with the Jews. 2. Lysias' perspective on that Sanhedrin debacle was essentially that Paul had said something about their law that was a controversial issue. 3. His assessment, which is quite vindicating for us reading Luke's narrative, is that this is nothing deserving of death OR imprisonment. Lysias essentially says that Paul is innocent of anything Rome might find against him. 4. We might wonder why Paul will have to wait over two and a half years to be released from Roman custody if the Roman officer in charge thinks he should go free… but we will see that there is a lot more political intrigue left to go in the book of Acts. vi. The third point is consistent except it reveals not only that Lysias has saved Paul once again, but that he plans to tell Paul's accusers to go to Caesarea to state their case before Felix. vii. We'll talk more about Felix next week. He is a rather… interesting character to say the least. e. [Slide 10] 31 - So, the soldiers, according to their orders, took Paul and brought him by night to Antipatris. 32 - But the next day, leaving the horsemen to go on with him, they returned to the barracks. 33 - When these had come to Caesarea and delivered the letter to the governor, they also presented Paul to him. i. So, we see that the soldiers followed Lysias' orders and took Paul by night to Antipatris, which was a military fort about 37 miles from Jerusalem. ii. Travelers from Caesarea and Jerusalem would often stop at this place for rest and provisions. iii. Traveling this far in one night, over half the journey to Caesarea, means they were BOOKIN. iv. Given the conditioning of a Roman soldier and the fact that they would travel a road which would be relatively unpopulated at night, it seems that they could cover the 37 miles in around 4-6 hours. This would put their arrival time at around 2am the following morning. v. After resting the remainder of the night, the next day the soldiers traveling on foot went back to Jerusalem, because at this point the danger on Paul's life would have been mitigated. vi. Only the 70 horsemen rode on with Paul to Caesarea. The remaining 23 miles could easily have been covered in an hour or two on horseback depending on the pace they wanted to set. vii. After arriving they finished their orders by giving the letter to Felix and presenting Paul to him. viii. This means that probably about the time that Lysais informs the Sanhedrin that Paul has been transferred to Felix in Caesarea, is about the same time that Paul is presented to Felix in Caesarea. f. [Slide 11] 34 - And when he had read it, he asked from what province he was, and when he learned that he was from Cilicia, 35 - he said, “I will give you a hearing after your accusers arrive also,” giving orders for him to be kept in Herod's Praetorium. i. Felix seems to be a good governor, at least initially. ii. He reads the letter and asks Paul from which Roman province he hails from. iii. The reason for this question is probably two-fold 1. First, to determine if he had jurisdiction over this person. a. We see a similar thing happen to Jesus and Pilate. Pilate, finding out that Jesus was from Galilee, sent him to Herod. b. If Felix could offload this case to someone else… he probably would. c. But Paul being from Cilicia would mean that he would still be within Felix's jurisdiction since Syria and Judea would have fallen in the same authority at this time. 2. Second, probably to check on the status of Paul being a Roman Citizen. a. As we said before, Roman records would be kept of citizenship, primarily in the cities or provincial capitals of your birthplace. b. No doubt Felix desires to make certain that Paul was indeed a Roman citizen. iv. Having heard that Paul is within his province he assures him that he will hear his case after his accusers arrive. v. In the meantime, Paul is to be held, again – in protective custody, in Felix's own home. A sprawling estate called Herod's Praetorium. vi. He is still a prisoner of Rome, so he is kept in the Praetorium, but he is probably afforded many liberties, including having his traveling companions either stay there with him or able to visit often. vii. This is why as we go forward into chapter 24, the pronoun “we” will begin to be in use again. Informing us subtly that Luke has joined the apostle. g. [Slide 12] Summary of the Point: In the last point we saw that God allows men to make evil plans. But in this point we see that God not only allows men to plan their wicked deeds… He even orchestrates and uses these wicked deeds to get His apostle one step closer to Rome. In this we see Proverbs 16:9 come screaming through. Men make their plans but the Lord guides their steps. These wicked Jews inadvertently forced the Roman commander to move Paul out of Jerusalem where he would eventually be moved to Rome, as the Lord Jesus said he would. By their wicked scheme, the Lord ushered His apostle to where He wanted him to go. In this the application is the same. We must trust the Lord. The role of many prophets in the Old Testament was to call the current Israelites to remember what God had done for them in the past so they could trust Him for their future. Occasionally our Lord recalls to us things we have experienced in our lives and traces His fingerprints on those events to show us how He has guided us to the exact spot we are in. Can I submit to you that in those cases, God provides merely an example of what He ALWAYS DOES! Meaning that even when we cannot see His hand guiding the events of our life to His design for us – that doesn't make it any less true. Thus we must trust the Lord! For all our ways are known to Him for He has planned them from before the foundation of the world. Conclusion: So, CBC, what have we learned today and how then shall we live? What are some basic applications for faith and practice we get from this text? Basics of Faith and Practice: [Slide 13] Once again, we are confronted with the paradoxical truths that mankind operates with free agency and responsibility for his actions, but God is in absolute and sovereign control over all things in His creation, including the decisions and choices of men. While we may be tempted to steal from one of these truths to help the other, this truth has long been summarized in Proverbs 16:9 and is on display in our text this morning. Man makes his plans but the Lord guides His steps. Mankind has free agency and responsibility to choose his path according to what has been revealed to him. But as the saying goes, you don't know what you don't know. God's eternal decreed will is hidden and therefore, He who has ordained every day has also orchestrated every event to accomplish the counsel of His will. In the text today we see God allow and orchestrate the wicked schemes of men to move His apostle toward Rome. So what is our response? What is our responsibility and our agency? It is to trust the Lord, that He is good, and that all things work together for good for those who love God and are called according to His purpose. What are some specific expressions of these rules for faith and practice? 1.) [Slide 14] Mind Transformation: “What truth must we believe from this text?” or “What might we not naturally believe that we must believe because of what this text has said?” We must affirm that God orchestrates even wicked schemes and political power grabs to accomplish His perfect will. a. Again, I'll try not to spend too much time on this, since this seems to be a point that Luke will beat into our heads for the remainder of the book of Acts. b. But still, it is worth noting, that not only sins of passion but even premeditated sins, sown in secret, to do terrible things, are orchestrated by God to accomplish His purposes. c. Even self-serving political opportunists, like Claudius Lysias who clearly just wants to climb the ladder of power, even this is orchestrated by the Lord to accomplish His will. d. Everything in this text serves to get Paul to Rome safely. Even the selfishness of Lysias and even the bloodthirstiness of the Jews. e. If God can work even these things to accomplish His will, do you think He can't do the same in your life? f. Have you ever had 40 men devise a plot to kill you? Have you ever had political opportunists use you as a bargaining chip for personal profit? Ok… don't answer that.

Hey Momma! Is this your first baby? Or maybe it has been a while since your last pregnancy and you are trying to prepare yourself for the journey ahead. Either way, this episode is going to let you in on (many but not all) the things that can happen during pregnancy, delivery and postpartum, so that you can be more prepared than the rest of us! I polled over a hundred women to see what they wish they knew and now I'm giving you all the goodies!    Books like What to Expect When You Are Expecting, can be very helpful but many times we don't really think all those “crazy or scary” things can actually happen to us.  Or maybe you had no idea it could happen at all! Informing yourself beforehand can help you better prepare for the unexpected.. Because believe me there will be lots of that! But also help you realize you are not alone! So many moms suffer being told “its normal”, “ you are cleared”, “It will go away after baby comes out” only to find in reality, that is not always the case and we could have done something about it! Thats why in this week's episode we are talking about all those things we wish we knew… and I am sure that there are many I have not included and will probably do a part II, but for now I hope this episode helps inform and support you throughout your prenatal, birth and postpartum journey!    If you want more support, reach out for coaching, join my FREE and Private support group below and DOWNLOAD my new APP Pelvic Floor, Core & More that has my on demand 12 wk program, tracking features, pelvic floor 101 masterclass and more!    RESTORE is my first 12 wk online signature program hosted inside my new platform that will be an APP soon Pelvic Floor, Core & More! Inside that program I walk you through the basics of healing, restoring your breathing, posture, core function and overall strength and return to impact and intensity.  All with the guidance of me, a Pelvic Floor PT, in your pocket making sure that you are getting individualized support and feedback through the program during our weekly group coaching calls! This option is great for those that can't afford a one-on-one session for $200-$240, those that don't have access to a pelvic floor PT in person or those that want to have a structured organized program with support as they are phasing out of acute therapy treatments and working more independently.    

Why does communication between executive directors and boards break down so often—even when everyone has the best intentions? In this episode of Inspired Nonprofit Leadership, host Sarah Olivieri unpacks the five biggest reasons board–ED communication goes sideways, from unclear decision-making lines to insecurity and information overload. With a blend of insight and tough love, Sarah shares what really causes the tension and what you can do to fix it—so your board and leadership can finally get on the same page and keep your nonprofit moving forward. Episode Highlights 01:12 Introduction to Communication Breakdowns 02:16 Reason 1: Strategic vs. Day-to-Day Decisions 03:38 Reason 2: Asking for Permission vs. Informing 04:43 Reason 3: Insecurity in Leadership 06:21 Reason 4: Board Members' Concerns 08:01 Reason 5: Overloading with Details 10:00 Conclusion and Final Thoughts Resource The Board Clarity Club A monthly membership for boards that provides training and live expert support to help your board have total clarity on how to be the best board possible. Learn More >> About Your Host Have you seen Casino Royale? That moment when Vespa slides in elegantly, opposite James, all charming smile, razor-sharp wit and mighty brainpower, and says, “I'm the money”? Well, your host, Sarah Olivieri has been likened to Vespa by one of her clients – not just because she's charming, beautiful and brainy– but because that bold statement “I'm the money” was, as it turned out, right ON the money. Sarah helps nonprofits transform their organizations from failing to thriving. And she's very, very good at it. She's brought nonprofits back from the brink of insolvency. She's averted major cash-flow crises, solved funding droughts, board conflicts and everything in between… and so she has literally become “the money” for many of the organizations she works with. As the former director of 3 nonprofits and founder of 5 for-profit businesses, she understands, deeply, the challenges and complexities facing organizations and she's created a framework, called The Impact Method®️, which can help you simplify operations, build aligned teams and make a bigger impact without getting overwhelmed or burning out – and Every. Single. One. Of her clients that have implemented her methodologies have achieved the most incredible results. Sarah is also a #1 international bestselling author, holds a BA from the University of Chicago with a focus on globalization and its effect on marginalized cultures, and a master's degree in Humanistic and Multicultural Education from SUNY New Paltz. Access additional training at www.pivotground.com/funding-secrets or apply for the THRiVE Program for personalized support at www.pivotground.com/application Be sure to subscribe to Inspired Nonprofit Leadership so that you don't miss a single episode, and while you're at it, won't you take a moment to write a short review and rate our show? It would be greatly appreciated! Let us know the topics or questions you would like to hear about in a future episode. You can do that and follow us on LinkedIn.

Cora is a psychotherapist and an artist.She has been practicing art psychotherapy since graduating from Loyola Marymount University (LMU) in 2005. She obtained her California Marriage and Family Therapist license and Art Therapy Registration in 2010. She opened her private practice in 2010, and received her Doctorate in Clinical Psychology (Psy.D) in 2018.In 2006, she and her husband Ray opened Gallery Azul in San Pedro, named after their child, Harmony AZUL Vasquez. They initially opened to showcase their artwork, but then began to invite other artists. Gallery Azul enjoys holding group art exhibitions that focus on informing and educating the community.Cora was the first in her family — immediate and extended — to obtain a Bachelor's degree, a Master's degree, and a Psy. D (Doctoral in Clinical Psychology)."Art is an ever evolving and ongoing part of my life, it is my cathartic expression, and the place in which I sublimate any residual from my clients and the world." -- Cora Ramirez-Vasquezwww.instagram.com/galleryazulWebsite: galleryazul.com and coraramirezvasquez.com 

Informing, entertaining and connecting isolated farmers was a prime goal of the Radio Broadcasting Company, officially incorporated in August 1925 and a forerunner to RNZ. As RNZ celebrates the centenary, Country Life dips back into the archives to bring you some of the well-loved voices and shows from the rural team over the decades. You can find photos and read more about this episode on our webpage, here.With thanks to:Ngā Taonga Sound & VisionMake sure you're following us on your favourite podcast app, so you don't miss new episodes every Friday evening.Want to chat to us or find out more about RNZ Podcasts? Join the RNZ Podcasts Discussion FacebookGo to this episode on rnz.co.nz for more details

In this episode of Euphoric Evolution, Makhosi and Joanna Murphy explore the deep connections between personal growth, entrepreneurship, and the importance of creative expression. Joanna shares her journey from being a competitive athlete to a successful entrepreneur, emphasizing the inner work required to achieve external success. They discuss the significance of embracing the process, setting boundaries, and the power of informing others in relationships. The conversation highlights the need for authenticity and connection in both personal and professional realms, especially in a rapidly changing world.TakeawaysJoanna's journey from athletics to entrepreneurship highlights the importance of inner transformation.Success is often an inside game, requiring self-discovery and growth.Embracing the process rather than focusing solely on outcomes leads to fulfillment.Creative expression enriches life and can positively impact business.Setting clear boundaries is essential for healthy business relationships.Informing others about your process fosters better communication and understanding.Navigating change requires a focus on adding value and serving others.Work can be a vehicle for personal evolution and growth.Authenticity in business leads to deeper connections with clients.Limitations can create freedom and enhance creativity.Support the show

Scientists, leaders, and patients discuss the intersection of cutting-edge science and real-world impact. They explore the importance of patient perspectives in shaping medical advancements and how collaboration fuels groundbreaking research. Key scientific achievements in areas like regenerative medicine, cancer therapies, and space biology are highlighted. The group emphasizes the need for scientists to engage more with the public—through social media and media appearances—to help people understand and value the life-changing discoveries in science. Featuring: Catriona Jamieson, M.D., Ph.D. UC San Diego Sandra Dillon Patient Advocate Alexander Khalessi, M.D., M.B.A. UC San Diego Jana Stoudemire Celestial Strategy, LLC Alysson Muotri, Ph.D. UC San Diego Rebecca Moores Philanthropist and Patient Advocate Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40519]

Scientists, leaders, and patients discuss the intersection of cutting-edge science and real-world impact. They explore the importance of patient perspectives in shaping medical advancements and how collaboration fuels groundbreaking research. Key scientific achievements in areas like regenerative medicine, cancer therapies, and space biology are highlighted. The group emphasizes the need for scientists to engage more with the public—through social media and media appearances—to help people understand and value the life-changing discoveries in science. Featuring: Catriona Jamieson, M.D., Ph.D. UC San Diego Sandra Dillon Patient Advocate Alexander Khalessi, M.D., M.B.A. UC San Diego Jana Stoudemire Celestial Strategy, LLC Alysson Muotri, Ph.D. UC San Diego Rebecca Moores Philanthropist and Patient Advocate Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40519]

Scientists, leaders, and patients discuss the intersection of cutting-edge science and real-world impact. They explore the importance of patient perspectives in shaping medical advancements and how collaboration fuels groundbreaking research. Key scientific achievements in areas like regenerative medicine, cancer therapies, and space biology are highlighted. The group emphasizes the need for scientists to engage more with the public—through social media and media appearances—to help people understand and value the life-changing discoveries in science. Featuring: Catriona Jamieson, M.D., Ph.D. UC San Diego Sandra Dillon Patient Advocate Alexander Khalessi, M.D., M.B.A. UC San Diego Jana Stoudemire Celestial Strategy, LLC Alysson Muotri, Ph.D. UC San Diego Rebecca Moores Philanthropist and Patient Advocate Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40519]

Scientists, leaders, and patients discuss the intersection of cutting-edge science and real-world impact. They explore the importance of patient perspectives in shaping medical advancements and how collaboration fuels groundbreaking research. Key scientific achievements in areas like regenerative medicine, cancer therapies, and space biology are highlighted. The group emphasizes the need for scientists to engage more with the public—through social media and media appearances—to help people understand and value the life-changing discoveries in science. Featuring: Catriona Jamieson, M.D., Ph.D. UC San Diego Sandra Dillon Patient Advocate Alexander Khalessi, M.D., M.B.A. UC San Diego Jana Stoudemire Celestial Strategy, LLC Alysson Muotri, Ph.D. UC San Diego Rebecca Moores Philanthropist and Patient Advocate Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40519]

Scientists, leaders, and patients discuss the intersection of cutting-edge science and real-world impact. They explore the importance of patient perspectives in shaping medical advancements and how collaboration fuels groundbreaking research. Key scientific achievements in areas like regenerative medicine, cancer therapies, and space biology are highlighted. The group emphasizes the need for scientists to engage more with the public—through social media and media appearances—to help people understand and value the life-changing discoveries in science. Featuring: Catriona Jamieson, M.D., Ph.D. UC San Diego Sandra Dillon Patient Advocate Alexander Khalessi, M.D., M.B.A. UC San Diego Jana Stoudemire Celestial Strategy, LLC Alysson Muotri, Ph.D. UC San Diego Rebecca Moores Philanthropist and Patient Advocate Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40519]

Scientists, leaders, and patients discuss the intersection of cutting-edge science and real-world impact. They explore the importance of patient perspectives in shaping medical advancements and how collaboration fuels groundbreaking research. Key scientific achievements in areas like regenerative medicine, cancer therapies, and space biology are highlighted. The group emphasizes the need for scientists to engage more with the public—through social media and media appearances—to help people understand and value the life-changing discoveries in science. Featuring: Catriona Jamieson, M.D., Ph.D. UC San Diego Sandra Dillon Patient Advocate Alexander Khalessi, M.D., M.B.A. UC San Diego Jana Stoudemire Celestial Strategy, LLC Alysson Muotri, Ph.D. UC San Diego Rebecca Moores Philanthropist and Patient Advocate Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40519]

Scientists, leaders, and patients discuss the intersection of cutting-edge science and real-world impact. They explore the importance of patient perspectives in shaping medical advancements and how collaboration fuels groundbreaking research. Key scientific achievements in areas like regenerative medicine, cancer therapies, and space biology are highlighted. The group emphasizes the need for scientists to engage more with the public—through social media and media appearances—to help people understand and value the life-changing discoveries in science. Featuring: Catriona Jamieson, M.D., Ph.D. UC San Diego Sandra Dillon Patient Advocate Alexander Khalessi, M.D., M.B.A. UC San Diego Jana Stoudemire Celestial Strategy, LLC Alysson Muotri, Ph.D. UC San Diego Rebecca Moores Philanthropist and Patient Advocate Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40519]

Scientists, leaders, and patients discuss the intersection of cutting-edge science and real-world impact. They explore the importance of patient perspectives in shaping medical advancements and how collaboration fuels groundbreaking research. Key scientific achievements in areas like regenerative medicine, cancer therapies, and space biology are highlighted. The group emphasizes the need for scientists to engage more with the public—through social media and media appearances—to help people understand and value the life-changing discoveries in science. Featuring: Catriona Jamieson, M.D., Ph.D. UC San Diego Sandra Dillon Patient Advocate Alexander Khalessi, M.D., M.B.A. UC San Diego Jana Stoudemire Celestial Strategy, LLC Alysson Muotri, Ph.D. UC San Diego Rebecca Moores Philanthropist and Patient Advocate Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40519]

Scientists, leaders, and patients discuss the intersection of cutting-edge science and real-world impact. They explore the importance of patient perspectives in shaping medical advancements and how collaboration fuels groundbreaking research. Key scientific achievements in areas like regenerative medicine, cancer therapies, and space biology are highlighted. The group emphasizes the need for scientists to engage more with the public—through social media and media appearances—to help people understand and value the life-changing discoveries in science. Featuring: Catriona Jamieson, M.D., Ph.D. UC San Diego Sandra Dillon Patient Advocate Alexander Khalessi, M.D., M.B.A. UC San Diego Jana Stoudemire Celestial Strategy, LLC Alysson Muotri, Ph.D. UC San Diego Rebecca Moores Philanthropist and Patient Advocate Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40519]

Today's agenda:  The manual of me Cringe corporate speak: take it offline Hot topic: all things start-ups: how to be successful, key traits and how to survive in an evolving organization What is it like working as an HR professional in a start-up? Reactivity vs. proactivity Working in an unpredictable and evolving environment can be an effective way to grow in your career Opportunities to build departments from the ground up RSUs and equity Informing and influencing on the job - it's not for everybody How do HR and all other business professionals, employees and leaders help shape a healthy startup culture? Questions/Comments  Your To-Do List: Grab merch, submit Questions & Comments, and make sure that you're the first to know about our In-Person Meetings (events!) at ⁠https://www.hrbesties.com⁠. Follow your Besties across the socials and check out our resumes here: ⁠https://www.hrbesties.com/about⁠.  Subscribe to the HR Besties Newsletter - ⁠https://hr-besties.beehiiv.com/subscribe⁠ We look forward to seeing you in our next meeting - don't worry, we'll have a hard stop! Yours in Business + Bullsh*t,  Leigh, Jamie & Ashley Follow Bestie Leigh! ⁠https://www.tiktok.com/@hrmanifesto⁠ ⁠https://www.instagram.com/hrmanifesto⁠ ⁠https://www.hrmanifesto.com⁠ Follow Bestie Ashley! ⁠https://www.tiktok.com/@managermethod⁠  ⁠https://www.instagram.com/managermethod⁠ ⁠https://www.linkedin.com/in/ashleyherd/⁠ ⁠https://managermethod.com⁠ Follow Bestie Jamie! ⁠https://www.millennialmisery.com/⁠ Humorous Resources: ⁠Instagram⁠ • ⁠YouTube⁠ • ⁠Threads⁠ • ⁠Facebook⁠ • ⁠X⁠ Millennial Misery: ⁠Instagram⁠ • ⁠Threads⁠ • ⁠Facebook⁠ • ⁠X⁠ Horrendous HR: ⁠Instagram⁠ • ⁠Threads⁠ • ⁠Facebook⁠ Tune in to “HR Besties,” a business, work and management podcast hosted by Leigh Elena Henderson (HRManifesto), Ashley Herd (ManagerMethod) and Jamie Jackson (Humorous_Resources), where we navigate the labyrinth of corporate culture, from cringe corporate speak to toxic leadership. Whether you're in Human Resources or not, corporate or small business, we offer sneak peeks into surviving work, hiring strategies, and making the employee experience better for all. Tune in for real talk on employee engagement, green flags in the workplace, and how to turn red flags into real change. Don't miss our chats about leadership, career coaching, and takes from work travel and watercooler gossip. Get new episodes every Wednesday, follow us on socials for the latest updates, and join us at our virtual happy hours to share your HR stories. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Biological oceanographer John Ryan joins Mongabay's podcast to discuss his team's multiyear study that examined vocalizations of baleen whales, including blue (Balaenoptera musculus), humpback (Megaptera novaeangliae) and fin whales (Balaenoptera physalus), and how this science is critical for understanding their feeding habits, and thus informing their conservation. The study found that these whales' songs rise and fall with their food supply, which provides valuable insights into how changing ocean conditions can affect their health and guide management measures. “Some of the research we did tracking the movement and ecology of blue whales helped our sanctuary [to] act on this long-term concern about ship strikes, and to join a program that is called Protecting Blue Whales and Blue Skies,” the Monterey Bay Aquarium Research Institute (MBARI) researcher says. Subscribe to or follow the Mongabay Newscast wherever you listen to podcasts, from Apple to Spotify, and you can also listen to all episodes here on the Mongabay website. This episode is dedicated to the memory of Mongabay's East Africa editor, Ochieng' Ogodo. Read here about his life, legacy and achievements. Audio credit: Blue and humpback whale calls featured in this episode are courtesy of MBARI and John Ryan. Image credit: A humpback whale dips back beneath the surface of the ocean. Image courtesy of Cristina Mittermeier/SeaLegacy. ------- Timecodes (00:00) Marine heatwaves and their impact (06:33) Analyzing whale songs (12:30) A change in tune (20:13) Interspecies communication? (25:16) The reason behind the heat (27:36) Informing conservation (36:52) Credits

As blood-based Alzheimer's disease (AD) biomarkers emerge, how can they change primary care's role in AD diagnosis? Credit available for this activity expires: 4/17/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/informing-alzheimers-disease-referral-blood-based-biomarker-2025a10008tl?ecd=bdc_podcast_libsyn_mscpedu

“Together we can build a thriving future for the building industry globally.” Duayne Pearce. I was raised on the smell of sawdust and paint fumes, spending countless hours on building worksites around South East Queensland, with my idol and best mate, my tradie Dad. I fully immersed myself in an industry that I would ultimately find irresistible. It was obvious from the get-go that an ever-present sense of tension between workers, bosses and customers was the way business was done. But more apparent was that money always seemed to be a problem. Nevertheless, leaving school early I jumped in with both feet. I worked hard, became a licensed builder and carpenter, and then reached the dizzying heights of what would appear on the outside to be an incredible success. The cars, the boats, the properties and even the accolades were afforded by our skyrocketing business turnover, but it was all a thin veneer. Underneath, my business was in danger of going bust and I was heading down that familiar rabbit hole of chronic stress, tension and inevitable outcomes of anxiety and depression. Like many contractors before me, I was about to lose everything. My rock bottom thankfully came with a silver lining and the wherewithal to reach out to my wife, friends and my team to try and sort things out. We worked together and took small steps to turn things around but I knew that I needed more help with structure and process. Business Coaches were part of the solution, but my ah-ha moment was realising none of the ones I had engaged understood or had experience in the building industry. That was my light-bulb moment. I'd found my niche and the journey to re-invent and elevate the industry that has always been so important to me, began. Now, with many collaborators and several innovations under my belt, it's my vision to level up the building industry. I'm on a mission to help others who are just like I was, struggling to make a living, working in one of the most important industries in the country. Informing, guiding, training and speaking are the tools of my trade that push for a revolution in the way residential builders and contractors approach their business to thrive. In doing so, we make vital inroads on how this multi-billion dollar industry is perceived positively by homeowner clients, the community and importantly the next generation of contractors choosing it as their own rewarding career. Hosted on Acast. See acast.com/privacy for more information.

In this episode of Stronger Sales Teams, Ben Wright explores the strategic development and application of sales literature in B2B sales management. Addressing the common challenge of content creation and drawing inspiration from the dynamic global sales landscape, Ben outlines key strategies to boost the impact and efficiency of sales teams. This discussion highlights the significance of crafting engaging, informative, and inspiring sales materials to build and sustain a high-performing B2B sales team. Key Takeaways: Introducing customers to your brand through concise and impactful presentation decks can set the stage for deeper client relationships. Detailed and engaging quotation templates are essential for standing out in a saturated market and effectively communicating your offerings. Leveraging capability statements filled with case studies and testimonials can boost credibility and inspire customer confidence. Prominently featuring customer testimonials and successful case studies acts as powerful tools for validating your brand's capability. Utilizing digital signatures and easy-to-read formats can optimize the client experience and streamline administrative processes. Time Stamps: 0:00 Intro 2:35 Types of Sales Materials or Sales Literature That Sales Teams Need 4:49 Engaging the Customers 6:10 Baseline Presentation Deck 13:44 Informing the Customers 18:00 Inspiring Customers 21:00 Recap 22:06 Iron Man Triathlon 22:57 Outro Rate, Review, & Follow If you're liking what you're hearing, make sure you ‘follow' the show wherever you listen to your podcasts…so you never miss an episode! I'd also love to hear what you think, so drop us a review after you close that next deal…tell me what you're liking, and what you want more of so I can look to cover it in a future episode.

Explore the cutting-edge intersection of space travel, biology, and health. Experts dive into the effects of microgravity and space radiation on mitochondrial function, DNA repair, and liver regeneration, shedding light on the unique challenges astronauts face during long-term missions. The discussion also touches on metabolic health, highlighting the role of diet and new pharmaceutical treatments like GLP-1 agonists in addressing modern-day health concerns. With engaging insights on how space research can inform breakthroughs on Earth, this talk is a must-watch for anyone interested in the future of human health and space exploration. Series: "MIND - Medicine Informing Novel Discoveries" [Health and Medicine] [Science] [Show ID: 40388]

Explore the cutting-edge intersection of space travel, biology, and health. Experts dive into the effects of microgravity and space radiation on mitochondrial function, DNA repair, and liver regeneration, shedding light on the unique challenges astronauts face during long-term missions. The discussion also touches on metabolic health, highlighting the role of diet and new pharmaceutical treatments like GLP-1 agonists in addressing modern-day health concerns. With engaging insights on how space research can inform breakthroughs on Earth, this talk is a must-watch for anyone interested in the future of human health and space exploration. Series: "MIND - Medicine Informing Novel Discoveries" [Health and Medicine] [Science] [Show ID: 40388]

Explore the cutting-edge intersection of space travel, biology, and health. Experts dive into the effects of microgravity and space radiation on mitochondrial function, DNA repair, and liver regeneration, shedding light on the unique challenges astronauts face during long-term missions. The discussion also touches on metabolic health, highlighting the role of diet and new pharmaceutical treatments like GLP-1 agonists in addressing modern-day health concerns. With engaging insights on how space research can inform breakthroughs on Earth, this talk is a must-watch for anyone interested in the future of human health and space exploration. Series: "MIND - Medicine Informing Novel Discoveries" [Health and Medicine] [Science] [Show ID: 40388]

Explore the cutting-edge intersection of space travel, biology, and health. Experts dive into the effects of microgravity and space radiation on mitochondrial function, DNA repair, and liver regeneration, shedding light on the unique challenges astronauts face during long-term missions. The discussion also touches on metabolic health, highlighting the role of diet and new pharmaceutical treatments like GLP-1 agonists in addressing modern-day health concerns. With engaging insights on how space research can inform breakthroughs on Earth, this talk is a must-watch for anyone interested in the future of human health and space exploration. Series: "MIND - Medicine Informing Novel Discoveries" [Health and Medicine] [Science] [Show ID: 40388]

Explore the cutting-edge intersection of space travel, biology, and health. Experts dive into the effects of microgravity and space radiation on mitochondrial function, DNA repair, and liver regeneration, shedding light on the unique challenges astronauts face during long-term missions. The discussion also touches on metabolic health, highlighting the role of diet and new pharmaceutical treatments like GLP-1 agonists in addressing modern-day health concerns. With engaging insights on how space research can inform breakthroughs on Earth, this talk is a must-watch for anyone interested in the future of human health and space exploration. Series: "MIND - Medicine Informing Novel Discoveries" [Health and Medicine] [Science] [Show ID: 40388]

Explore the cutting-edge intersection of space travel, biology, and health. Experts dive into the effects of microgravity and space radiation on mitochondrial function, DNA repair, and liver regeneration, shedding light on the unique challenges astronauts face during long-term missions. The discussion also touches on metabolic health, highlighting the role of diet and new pharmaceutical treatments like GLP-1 agonists in addressing modern-day health concerns. With engaging insights on how space research can inform breakthroughs on Earth, this talk is a must-watch for anyone interested in the future of human health and space exploration. Series: "MIND - Medicine Informing Novel Discoveries" [Health and Medicine] [Science] [Show ID: 40388]

Explore the cutting-edge intersection of space travel, biology, and health. Experts dive into the effects of microgravity and space radiation on mitochondrial function, DNA repair, and liver regeneration, shedding light on the unique challenges astronauts face during long-term missions. The discussion also touches on metabolic health, highlighting the role of diet and new pharmaceutical treatments like GLP-1 agonists in addressing modern-day health concerns. With engaging insights on how space research can inform breakthroughs on Earth, this talk is a must-watch for anyone interested in the future of human health and space exploration. Series: "MIND - Medicine Informing Novel Discoveries" [Health and Medicine] [Science] [Show ID: 40388]

Explore the cutting-edge intersection of space travel, biology, and health. Experts dive into the effects of microgravity and space radiation on mitochondrial function, DNA repair, and liver regeneration, shedding light on the unique challenges astronauts face during long-term missions. The discussion also touches on metabolic health, highlighting the role of diet and new pharmaceutical treatments like GLP-1 agonists in addressing modern-day health concerns. With engaging insights on how space research can inform breakthroughs on Earth, this talk is a must-watch for anyone interested in the future of human health and space exploration. Series: "MIND - Medicine Informing Novel Discoveries" [Health and Medicine] [Science] [Show ID: 40388]

Governor Glenn Youngkin is considering a bill aimed at cracking down on invasive plants. Michael Pope has the story.

With the help of Teacher-Powered Schools, Socol-Moran Partners, Stimpunks, and What School Could Be, we've officially announced our 4th annual virtual Conference to Restore Humanity for July 21-23, focused this year on the Quest for Connection. If you're interested in joining us, tickets start at just 50 bucks and you can find the full lineup at humanrestorationproject.org/conferenceToday I'm joined by Christian Moore-Anderson. And I wanted to have Christian on to talk about the ideas that drive his teaching practice and that he shares in his book, Difference Maker: Enacting systems theory in biology teaching. While that title may seem daunting, Christian's teaching would immediately look and feel to observers like “just good teaching.” But that's just the tip of the iceberg. Informing his theory and practice of teaching is a set of related ideas that I was largely unfamiliar with before encountering it in his book: cybernetics, systems theory, and enactivism. Cybernetics is simply a feedback loop. Just as someone steering a ship adjusts the rudder based on feedback from the ocean, so too does good pedagogy depend on what Christian calls “recursive teaching”, or a constant feedback loop of action, interpretation, and learning between teachers and students. You can connect with Christian on BlueSky @cmooreanderson.bsky.social.Difference Maker: Enacting Systems Theory in Biology Teaching - Christian Moore-AndersonChristian's Recommended Reading:From Being to Doing: The Origins of the Biology of Cognition - Humberto Maturana, Bernhard PörksenThe Pragmatic Turn: Toward Action-Oriented Views in Cognitive Science Edited by Andreas K. Engel, Karl J. Friston and Danica Kragic Understanding Systems: Conversations on Epistemology and Ethics - Heinz von Foerster The Cybernetic Brain: Sketches of Another Future - Andrew Pickering Runaway: Gregory Bateson, the Double Bind, and the Rise of Ecological Consciousness - Anthony Chaney Hosted on Acast. See acast.com/privacy for more information.

TOM'S BIO  On March 5, 2025, Tom Llamas was named as Lester Holt's successor as anchor and managing editor of NBC Nightly News beginning in summer 2025. This episode is a re-released show originally released on October 26, 2023. Tom's life and career are remarkable and he is a master of truth telling and the news media. He is an American journalist who was the weekend anchor for World News Tonight on ABC and is now Senior National Correspondent and anchor for NBC News Now, hosting Top Story with Tom Llamas, as well as substituting occasionally in NBC's Today and NBC Nightly News.  He has won multiple Emmy Awards for "Best Anchor" and "Best Hard News Story as well an Edward R. Murrow award for his coverage of Hurricane Sandy. His first Emmy award was tied to his brilliant reporting on human smuggling and an interdiction at sea with the U.S. Coast Guard.  Llamas career in a nutshell: NBC News Specials Unit, MSNBC political reporting, NBC's WTVJ in Miami, WNBC in New York, NBC News, ABC News as sole weekend anchor and now back at NBC. Tom has covered the most important stories in recent history: The 2020 presidential race,  the immigration crisis from the U.S. border with Mexico contributed, the death of U.S. war hero Senator John McCain, the rescue mission of the 12 Thai boys trapped in a cave, the sentencing of Bill Cosby, the mass shooting at Marjory Stoneman Douglas High School and many others. He has interviewed President Donald Trump, President Volodymyr Zelensky and Venezuelan President Nicolas Maduro.  Llamas was born and raised in Miami after his parents fled from Cuba during the 1960s. He graduated from Loyola University in New Orleans and lives in Manhattan. EPISODE OUTLINE (0:00) - Intro (0:38) - Bio (01:06) - Discovering a talent, nurturing it, developing it; background informs perspective (02:40) - Getting into the business; Telemundo at 15 years old (04:48) - The path, learning the business, starting at the bottom (05:48) - Media changing, citizen journalism; pros and cons, the future (07:25) - Careers in new media, digital distribution, democratizing fame (08:55) - Training as a journalist, ethics, laws, impartiality; 10,000 reps (10:38) - Americans love variety; from burgers to tomato sauce to news (11:42) - A story that sticks out

Today we are interviewing special guests Drass and Mottzy from Drattzy Games, about their upcoming title Alterium Shift! And also talking about all the OTHER cool RPG stuff from this week! Play the Demo and Wishlist Alterium Shift: https://store.steampowered.com/app/1586990/Alterium_Shift/ Join the last push on the Kickstarter! https://www.kickstarter.com/projects/drattzygames/alterium-shift✩ Audio Version ✩ ► https://superderekrpgs.com/hitpoint/ SOCIAL LINKS --------------------------------------------------- ✩ Derek ✩ ►Twitch: https://www.twitch.tv/SuperDerekRPGs►Bluesky: https://bsky.app/profile/superderekrpgs.com ►Youtube: https://www.youtube.com/@SuperDerek ►Discord: https://discord.me/superderek✩ Baku ✩ ►Twitch: https://www.twitch.tv/BakusanOG►Bluesky: https://bsky.app/profile/bakusanog.bsky.social ►Youtube: https://www.youtube.com/WeebSauce ►Discord: https://discord.me/ABC UPCOMING RELEASES --------------------------------------------------- ►Monster Hunter Wildshttps://www.youtube.com/watch?v=a_wNFT4j6qI  ►Suikoden I & II HD Remaster: Gate Rune and Dunan Unification Warshttps://www.youtube.com/watch?v=VIL88ZqQurQ GAME ANNOUNCEMENTS --------------------------------------------------- ►MADO MONOGATARI: Fia and the Wondrous Academy https://www.youtube.com/watch?v=ssV0H0rXIK0 ►Scar-Lead Salvationhttps://www.youtube.com/watch?v=yKwMv6z5ZZ8 ►KinnikuNeko: SUPER MUSCLE CAT https://www.youtube.com/watch?v=l2YZFe0uzNo ►Fuga: Melodies of Steel 3https://www.youtube.com/watch?v=If5Lzf_M9KU ►Yasha: Legends of the Demon Bladehttps://www.youtube.com/watch?v=OZmVEogYGlc ►The Lonesome Guildhttps://www.youtube.com/watch?v=dQWc-2nEqNE ►Pokemon Legends: Z-A https://www.youtube.com/watch?v=M_KNDtKJJ-8  ►Samurai Pizza Cats: Blast from the Past!https://www.youtube.com/watch?v=dgqr6mm6ZuI INDUSTRY NEWS --------------------------------------------------- Square Enix NieR series 15th anniversary live streamhttps://www.youtube.com/watch?v=3FQD3gUBShw TIMESTAMPS--------------------------------------------------- 0:00 Welcome back to HitPoint! 0:01:06 Intro0:01:37 A Long, Long Time Ago0:02:48 Baku, How Are You Doing?0:04:37 Derek, What's going on?Developer Interview:0:05:35 Interview with "Drass" and "Mottz"y from Drattzy Games, Alterium Shift0:07:15 How Did You Come Together?0:12:50 What Have Been the Biggest Challenges So Far?0:17:22 What Is a Popular Game You Dislike?0:20:27 What Are Some of Your Core Design Philosophies for Alterium Shift?0:23:07 Trailer Watch-Along0:26:37 Were Any Changes or Specific Choices Made Because of Derek's Feedback?0:32:13 How Do You Find a Balance Between Implementing Feedback vs. Your Original Vision?0:35:46 What Are Some of Your Primary Inspirations Behind Alterium Shift?0:39:25 How Difficult Is It to Keep Track of the Different Characters with Their Own Stories?0:42:34 Is the Intention to Play the Game Three Times or Shift Between the Characters?0:46:31 How Do You Create Your Games from Pixel Art to 3D Models?0:49:24 What Role Do Sound Design and Music Play in Informing the Atmosphere of Alterium Shift?0:52:07 Could You Discuss Some of the Technical Choices Behind Implementing Map Abilities?0:55:31 How Do You Plan to Balance Early Access with the Kickstarter?0:59:29 How Do You Envision the Transition from Early Access to a Full Game?1:02:43 How Do You Balance Taking Creative Risks with Practical Commercial Considerations?1:07:14 I Heard, Mottzy, That Your Employment Situation Will Change a Little Bit?1:09:31 Your Kickstarter Reached Its Funding Level and the First Stretch Goal?1:12:19 What Was the Catalyst for Making a Whole Bunch of Changes?1:17:14 Will You Also Change the Font?1:19:16 How Have You Made an Agile Development Process Work for You?1:27:26 How Long Do You Suppose You'd Like to Support the Game After Release?1:34:03 What Are Some Other Things You Can Share with Us About Future Projects?1:35:52 What Is Your Taylor Ratio?1:37:10 Is There a Question You Wish Was Asked?1:44:38 RetrospectiveUpcoming Releases This Week:1:46:30 Monster Hunter Wilds1:53:31 Suikoden I & II HD Remaster: Gate Rune and Dunan Unification WarsNew Games Announced:1:59:13 MADO MONOGATARI: Fia and the Wondrous Academy – 20252:02:31 Scar-Lead Salvation – 29 May 20252:04:29 KinnikuNeko: SUPER MUSCLE CAT – Console Release 19 March 20252:06:50 Fuga: Melodies of Steel 3 – 29 May 20252:11:45 Yasha: Legends of the Demon Blade – 24 April 20252:14:30 The Lonesome Guild – Fall 20252:17:20 Pokémon Legends: Z-A – Late 20252:25:47 Samurai Pizza Cats: Blast from the Past! – 2026Industry News:2:29:54 Square Enix NieR Series 15th Anniversary Live StreamResponding to Super Chats & Outro:2:33:42 Responding to Super Chats2:42:23 Outro

- Overview & Definition of Biomarkers - What are Some Examples of Biomarker Testing - How Biomarker Testing Provides Useful Information for Cancer Treatment - Why the Molecular Portrait of Cancer is so Important - The Role of the Pathologist - Benefits of Biomarker Testing & Precision Medicine - Predicting Response to Treatment - Clinical Trials: How Research Contributes to Your Treatment Options - Key Questions to Ask Your Health Care Team - Guidelines for Preparing for Telehealth Appointments with Your Health Care Team, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Quality-of-Life Concerns - Questions for Our Panel of Experts

- Overview & Definition of Biomarkers - What are Some Examples of Biomarker Testing - How Biomarker Testing Provides Useful Information for Cancer Treatment - Why the Molecular Portrait of Cancer is so Important - The Role of the Pathologist - Benefits of Biomarker Testing & Precision Medicine - Predicting Response to Treatment - Clinical Trials: How Research Contributes to Your Treatment Options - Key Questions to Ask Your Health Care Team - Guidelines for Preparing for Telehealth Appointments with Your Health Care Team, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Quality-of-Life Concerns - Questions for Our Panel of Experts

- Overview & Definition of Biomarkers - What are Some Examples of Biomarker Testing - How Biomarker Testing Provides Useful Information for Cancer Treatment - Why the Molecular Portrait of Cancer is so Important - The Role of the Pathologist - Benefits of Biomarker Testing & Precision Medicine - Predicting Response to Treatment - Clinical Trials: How Research Contributes to Your Treatment Options - Key Questions to Ask Your Health Care Team - Guidelines for Preparing for Telehealth Appointments with Your Health Care Team, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Quality-of-Life Concerns - Questions for Our Panel of Experts

- Overview & Definition of Biomarkers - What are Some Examples of Biomarker Testing - How Biomarker Testing Provides Useful Information for Cancer Treatment - Why the Molecular Portrait of Cancer is so Important - The Role of the Pathologist - Benefits of Biomarker Testing & Precision Medicine - Predicting Response to Treatment - Clinical Trials: How Research Contributes to Your Treatment Options - Key Questions to Ask Your Health Care Team - Guidelines for Preparing for Telehealth Appointments with Your Health Care Team, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Quality-of-Life Concerns - Questions for Our Panel of Experts

- Overview & Definition of Biomarkers - What are Some Examples of Biomarker Testing - How Biomarker Testing Provides Useful Information for Cancer Treatment - Why the Molecular Portrait of Cancer is so Important - The Role of the Pathologist - Benefits of Biomarker Testing & Precision Medicine - Predicting Response to Treatment - Clinical Trials: How Research Contributes to Your Treatment Options - Key Questions to Ask Your Health Care Team - Guidelines for Preparing for Telehealth Appointments with Your Health Care Team, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Quality-of-Life Concerns - Questions for Our Panel of Experts

- Overview & Definition of Biomarkers - What are Some Examples of Biomarker Testing - How Biomarker Testing Provides Useful Information for Cancer Treatment - Why the Molecular Portrait of Cancer is so Important - The Role of the Pathologist - Benefits of Biomarker Testing & Precision Medicine - Predicting Response to Treatment - Clinical Trials: How Research Contributes to Your Treatment Options - Key Questions to Ask Your Health Care Team - Guidelines for Preparing for Telehealth Appointments with Your Health Care Team, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Quality-of-Life Concerns - Questions for Our Panel of Experts

- Overview & Definition of Biomarkers - What are Some Examples of Biomarker Testing - How Biomarker Testing Provides Useful Information for Cancer Treatment - Why the Molecular Portrait of Cancer is so Important - The Role of the Pathologist - Benefits of Biomarker Testing & Precision Medicine - Predicting Response to Treatment - Clinical Trials: How Research Contributes to Your Treatment Options - Key Questions to Ask Your Health Care Team - Guidelines for Preparing for Telehealth Appointments with Your Health Care Team, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Quality-of-Life Concerns - Questions for Our Panel of Experts

- Overview & Definition of Biomarkers - What are Some Examples of Biomarker Testing - How Biomarker Testing Provides Useful Information for Cancer Treatment - Why the Molecular Portrait of Cancer is so Important - The Role of the Pathologist - Benefits of Biomarker Testing & Precision Medicine - Predicting Response to Treatment - Clinical Trials: How Research Contributes to Your Treatment Options - Key Questions to Ask Your Health Care Team - Guidelines for Preparing for Telehealth Appointments with Your Health Care Team, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Quality-of-Life Concerns - Questions for Our Panel of Experts

- Overview & Definition of Biomarkers - What are Some Examples of Biomarker Testing - How Biomarker Testing Provides Useful Information for Cancer Treatment - Why the Molecular Portrait of Cancer is so Important - The Role of the Pathologist - Benefits of Biomarker Testing & Precision Medicine - Predicting Response to Treatment - Clinical Trials: How Research Contributes to Your Treatment Options - Key Questions to Ask Your Health Care Team - Guidelines for Preparing for Telehealth Appointments with Your Health Care Team, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Quality-of-Life Concerns - Questions for Our Panel of Experts

- Overview & Definition of Biomarkers - What are Some Examples of Biomarker Testing - How Biomarker Testing Provides Useful Information for Cancer Treatment - Why the Molecular Portrait of Cancer is so Important - The Role of the Pathologist - Benefits of Biomarker Testing & Precision Medicine - Predicting Response to Treatment - Clinical Trials: How Research Contributes to Your Treatment Options - Key Questions to Ask Your Health Care Team - Guidelines for Preparing for Telehealth Appointments with Your Health Care Team, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Quality-of-Life Concerns - Questions for Our Panel of Experts

- Overview & Definition of Biomarkers - What are Some Examples of Biomarker Testing - How Biomarker Testing Provides Useful Information for Cancer Treatment - Why the Molecular Portrait of Cancer is so Important - The Role of the Pathologist - Benefits of Biomarker Testing & Precision Medicine - Predicting Response to Treatment - Clinical Trials: How Research Contributes to Your Treatment Options - Key Questions to Ask Your Health Care Team - Guidelines for Preparing for Telehealth Appointments with Your Health Care Team, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Quality-of-Life Concerns - Questions for Our Panel of Experts

- Overview & Definition of Biomarkers - What are Some Examples of Biomarker Testing - How Biomarker Testing Provides Useful Information for Cancer Treatment - Why the Molecular Portrait of Cancer is so Important - The Role of the Pathologist - Benefits of Biomarker Testing & Precision Medicine - Predicting Response to Treatment - Clinical Trials: How Research Contributes to Your Treatment Options - Key Questions to Ask Your Health Care Team - Guidelines for Preparing for Telehealth Appointments with Your Health Care Team, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Quality-of-Life Concerns - Questions for Our Panel of Experts

- Overview & Definition of Biomarkers - What are Some Examples of Biomarker Testing - How Biomarker Testing Provides Useful Information for Cancer Treatment - Why the Molecular Portrait of Cancer is so Important - The Role of the Pathologist - Benefits of Biomarker Testing & Precision Medicine - Predicting Response to Treatment - Clinical Trials: How Research Contributes to Your Treatment Options - Key Questions to Ask Your Health Care Team - Guidelines for Preparing for Telehealth Appointments with Your Health Care Team, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Quality-of-Life Concerns - Questions for Our Panel of Experts

Dr. Neeraj Agarwal and Dr. Peter Hoskin discuss key abstracts in GU cancers from the 2025 ASCO Genitourinary Cancers Symposium, including novel therapies in prostate, bladder, and kidney cancer and the impact of combination therapies on patient outcomes. TRANSCSRIPT Dr. Neeraj Agarwal: Hello, and welcome to the ASCO Daily News Podcast. I'm Dr. Neeraj Agarwal, the director of the Genitourinary Oncology Program and professor of medicine at the Huntsman Cancer Institute at the University of Utah, and editor-in-chief of ASCO Daily News. Today, we'll be discussing practice-informing abstracts and other key advances in GU oncology featured at the 2025 ASCO Genitourinary Cancers Symposium. Joining me for this discussion is Dr. Peter Hoskin, the chair of this year's ASCO GU Symposium. Dr. Hoskin is a professor in clinical oncology in the University of Manchester and honorary consultant in clinical oncology at the Christie Hospital, Manchester, and University College Hospital London, in the United Kingdom. Our full disclosures are available in the transcript of this episode. Peter, thank you for joining us today. Dr. Peter Hoskin: Thank you so much, Neeraj. I am very pleased to be here. Dr. Neeraj Agarwal: The GU meeting highlighted remarkable advancements across the spectrum of GU malignancies. What stood out to you as the most exciting developments at the ASCO GU Symposium?  Dr. Peter Hoskin: The theme of this year's meeting was "Driving Innovation, Improving Patient Care," and this reflected ASCO GU's incredible milestone in GU cancer research over the years. We were thrilled to welcome almost 6,000 attendees on this occasion from over 70 countries, and most of them were attending in person and not online, although this was a hybrid meeting. Furthermore, we had more than 1,000 abstract submissions. You can imagine then that it fostered fantastic networking opportunities and facilitated valuable knowledge and idea exchanges among experts, trainees, and mentees. So, to start I'd like to come back to you for a second because the first day started with a focus on prostate cancer and some of the key clinical trials. And congratulations to you, Neeraj, on sharing the data from the TALAPRO-2 trial, which we were eagerly awaiting. I'd love to get your thoughts on the data that you presented. Could you tell us more about that trial, Abstract LBA18?  Dr. Neeraj Agarwal: Yes, Peter, I agree with you. It was such an exciting conference overall and thank you for your leadership of this conference. So, let's talk about the TALAPRO-2 trial. First of all, I would like to remind our audience that the combination of talazoparib plus enzalutamide was approved by the U.S. FDA in June 2023 in patients with metastatic castration-resistant prostate cancer harboring HRR gene alterations, after this combination improved the primary endpoint of radiographic progression-free survival compared to enzalutamide alone in the randomized, double-blind, placebo-controlled, multi-cohort phase 3 TALAPRO-2 trial. In the abstract I presented at ASCO GU 2025, we reported the final overall survival data, which was a key alpha-protected secondary endpoint in cohort 1, which enrolled an all-comer population of patients with mCRPC. So, at a median follow-up of around 53 months, in the intention-to-treat population, the combination of talazoparib plus enzalutamide significantly reduced the risk of death by 20% compared to enzalutamide alone, with a median OS of 45.8 months in the experimental arm versus 37 months in the control arm, which was an active control arm of enzalutamide. This improvement was consistent in patients with HRR alterations with a hazard ratio of 0.54 and in those with non-deficient or unknown HRR status, with a hazard ratio of 0.87. In a post hoc analysis, the hazard ratio for OS was 0.78 favoring the combination in those patients who did not have any HRR gene alteration in their tumors by both tissue and ctDNA testing. Consistent with the primary analysis, the updated rPFS data also favored the experimental arm with a median rPFS of 33.1 compared to 19.5 months in the control arm, and a hazard ratio of 0.667. No new safety signals were identified with extended follow-up. Thus, TALAPRO-2 is the first PARP inhibitor plus ARPI study to show a statistically significant and a clinically meaningful improvement in OS compared to standard-of-care enzalutamide as first-line treatment in patients with mCRPC unselected for HRR gene alterations. Dr. Peter Hoskin: Thank you, Neeraj. That's a great summary of the data presented and very important data indeed. There was another abstract also featured in the same session, Abstract 20, titled “Which patients with metastatic hormone-sensitive prostate cancer benefit more from androgen receptor pathway inhibitors? STOPCAP meta-analyses of individual participant data.” Neeraj, could you tell us more about this abstract? Dr. Neeraj Agarwal: Absolutely, I would be delighted to. So, in this meta-analysis, Dr. David Fischer and colleagues pooled individual participant data from different randomized phase 3 trials in the mHSPC setting to assess the potential ARPI effect modifiers and determine who benefits more from an ARPI plus ADT doublet. The primary outcome was OS for main effects and PFS for subgroup analyses. Prostate cancer specific survival was a sensitivity outcome. The investigators pooled data from 11 ARPI trials and more than 11,000 patients. Overall, there was a clear benefit of adding an ARPI on both OS and PFS, with hazard ratios of 0.66 and 0.51, respectively, representing a 13% and 21% absolute improvement at 5 years, respectively, with no clear difference by the class of agent. When stratifying the patients by age group, the effects of adding an ARPI on OS and PFS were slightly smaller in patients older than 75, than in those younger than 65, or aged between 65 and 75 years. Notably, in the trials assessing the use of abiraterone, we saw very little OS effects in the group of patients older than 75, however there was some benefit maintained in prostate-cancer specific survival, suggesting that other causes of death may be having an impact. The effects of the other ARPIs, or ‘lutamides' as I would call them, were similar across all three age subgroups on both OS and PFS. Therefore, the majority of patients with mHSPC benefit from the addition of ARPIs, and the benefits/risks of abiraterone and other ‘amides' must be considered in older patients.  Dr. Peter Hoskin: Thanks, Neeraj. Another great summary relevant to our day-to-day practice. Of course, there's ongoing collection of individual patient data from other key trials, which will allow robust comparison of ARPI doublet with triplet therapy (including docetaxel), guiding more personalized treatment.   Dr. Neeraj Agarwal: I agree with you, Peter, we need more data to help guide personalized treatment for patients with mHSPC and potentially guide de-escalation versus escalation strategies. Now, moving on to a different setting in prostate cancer, would you like to mention Abstract 17 titled, “Overall survival and quality of life with Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in poor-risk, metastatic, castration-resistant prostate cancer in ENZA-p (ANZUP 1901),” presented by Dr. Louise Emmett? Dr. Peter Hoskin: Of course I will. So, ENZA-p was a multicenter, open-label, randomized, phase 2 trial conducted in Australia. It randomized 163 patients into adaptive doses (2 or 4 cycles) of Lu-PSMA-617 plus enzalutamide versus enzalutamide alone as first-line treatment in PSMA-PET-CT-positive, poor-risk, mCRPC. The interim analysis of ENZA-p with median follow-up 20 months showed improved PSA-progression-free survival with the addition of Lu-PSMA-617 to enzalutamide. Here, the investigators reported the secondary outcomes, overall survival, and health-related quality of life (HRQOL). After a median follow up of 34 months, overall survival was longer in the combination arm compared to the enzalutamide arm, with a median OS of 34 months compared to 26 months; with an HR of 0.55. Moreover, the combination improved both deterioration-free survival and health-related quality of life indicators for pain, fatigue, physical function, and overall health and quality of life compared to the control arm. Consistent with the primary analysis, the rPFS also favored the experimental arm with a median rPFS of 17 months compared to 14 months with a HR of 0.61. So, the addition of LuPSMA improved overall survival, and HRQOL in patients with high-risk mCRPC. Dr. Neeraj Agarwal: Thank you, Peter. Great summary, and promising results with Lu-177 and ARPI combination in first line treatment for mCRPC among patients who had two or more high risk features associated with early enzalutamide failure. Before we move on to bladder cancer, would you like to tell us about Abstract 15 titled, “World-wide oligometastatic prostate cancer (omPC) meta-analysis leveraging individual patient data (IPD) from randomized trials (WOLVERINE): An analysis from the X-MET collaboration,” presented by Dr. Chad Tang?  Dr. Peter Hoskin: Sure. So, with metastatic-directed therapy (MDT), we have a number of phase 2 studies making up the database, and the X-MET collaboration aimed to consolidate all randomized data on oligometastatic solid tumors. This abstract presented pooled individual patient data from all the published trials involving patients with oligometastatic prostate cancer who received MDT alongside standard of care (SOC) against SOC alone. The analysis included data from five trials, encompassing 472 patients with oligometastatic prostate cancer, and followed for a median of 41 months. Patients were randomly assigned in a 1:1 ratio to receive either MDT plus SOC or SOC alone. The addition of MDT significantly improved PFS. The median PFS was 32 months with MDT compared to 14.9 months with SOC alone, with an HR of 0.45. Subgroup analyses further confirmed the consistent benefits of MDT across different patient groups. Regardless of factors like castration status, receipt of prior primary treatment, stage, or number of metastases, MDT consistently improved PFS. In patients with mHSPC, MDT significantly delayed the time to castration resistance by nine months, extending it to a median of 72 months compared to 63 months in the SOC group with an HR of 0.58. In terms of OS, the addition of MDT improved the 48-month survival rate by 12%, with OS rates of 87% in the MDT+SOC group compared to 75% in the SOC alone group. Dr. Neeraj Agarwal: Thank you, Peter. These data demonstrate that adding MDT to systemic therapy significantly improves PFS, rPFS, and castration resistance-free survival, reinforcing its potential role in the treatment of oligometastatic prostate cancer. So, let's switch gears to bladder cancer and start with Abstract 658 reporting the OS analysis of the CheckMate-274 trial. Would you like to tell us about this abstract?  Dr. Peter Hoskin: Yes, sure, Neeraj. This was presented by Dr. Matt Milowsky, and it was additional efficacy outcomes, including overall survival, from the CheckMate-274 trial which evaluated adjuvant nivolumab versus placebo in patients with high-risk muscle-invasive bladder cancer after radical surgery. The phase 3 trial previously demonstrated a significant improvement in disease-free survival with nivolumab. With a median follow-up of 36.1 months, disease-free survival was longer with nivolumab compared to placebo across all patients with muscle-invasive bladder cancer, reducing the risk of disease recurrence or death by 37%. Among patients who had received prior neoadjuvant cisplatin-based chemotherapy, nivolumab reduced this risk by 42%, whilst in those who had not received chemotherapy, the risk was reduced by 31%. Overall survival also favored nivolumab over placebo, reducing the risk of death by 30% in all patients with muscle-invasive bladder cancer and by 52% in those with tumors expressing PD-L1 at 1% or higher. Among patients who had received prior neoadjuvant chemotherapy, nivolumab reduced the risk of death by 26%, whilst in those who had not received chemotherapy, the risk was reduced by 33%. Alongside this, the safety profile remained consistent with previous findings. Dr. Neeraj Agarwal: Thank you, Peter, for such a nice overview of this abstract. These results reinforce adjuvant nivolumab as a standard of care for high-risk muscle-invasive bladder cancer, offering the potential for a curative outcome for our patients. Dr. Peter Hoskin: I agree with you Neeraj. Perhaps you would like to mention Abstract 659 titled, “Additional efficacy and safety outcomes and an exploratory analysis of the impact of pathological complete response (pCR) on long-term outcomes from NIAGARA.” Dr. Neeraj Agarwal: Of course. Dr. Galsky presented additional outcomes from the phase 3 NIAGARA study, which evaluated perioperative durvalumab combined with neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer. The study previously demonstrated a significant improvement in event-free survival and overall survival with durvalumab compared to chemotherapy alone, with a manageable safety profile and no negative impact on the ability to undergo radical cystectomy. Among the 1,063 randomized patients, those who received durvalumab had a 33% reduction in the risk of developing distant metastases or death and a 31% reduction in the risk of dying from bladder cancer compared to those who received chemotherapy alone. More patients who received durvalumab achieved a pathological complete response at the time of surgery with 37% compared to 28% in the chemotherapy-alone group. Patients who achieved a pathological complete response had better event-free survival and overall survival compared to those who did not. In both groups, durvalumab provided additional survival benefits, reducing the risk of disease progression or death by 42% and the risk of death by 28% in patients with a pathological complete response, while in those patients without a pathological complete response, the risk of disease progression or death was reduced by 23% and the risk of death by 16% when durvalumab was added to the chemotherapy. Immune-mediated adverse events occurred in 21% of patients in the durvalumab group compared to 3% in the chemotherapy-alone group, with grade 3 or higher events occurring in 3% compared to 0.2%. The most common immune-related adverse events included hypothyroidism in 10% of patients treated with durvalumab compared to 1% in the chemotherapy-alone group, and hyperthyroidism in 3% versus 0.8%. At the time of the data cutoff, these adverse events had resolved in 41% of affected patients in the durvalumab group and 44% in the chemotherapy-alone group. Dr. Peter Hoskin: Thank you, Neeraj, for the great summary. These findings further support the role of perioperative durvalumab as a potential standard of care for patients with muscle-invasive bladder cancer. Dr. Neeraj Agarwal: I concur with your thoughts, Peter. Before wrapping up the bladder cancer section, would you like to mention Abstract 664 reporting updated results from the EV-302 trial, which evaluated enfortumab vedotin in combination with pembrolizumab compared to chemotherapy as first-line treatment for patients with previously untreated locally advanced or metastatic urothelial carcinoma? Dr. Peter Hoskin: Yes, of course. Dr. Tom Powles presented updated findings from the EV-302 study, and in this abstract presented 12 months of additional follow-up for EV-302 (>2 y of median follow-up) and an exploratory analysis of patients with confirmed complete response (cCR). The study had a median follow-up of 29.1 months and previously demonstrated significant improvements in progression-free survival and overall survival with enfortumab vedotin and pembrolizumab. This is now the standard of care in global treatment guidelines. Among the 886 randomized patients, enfortumab vedotin and pembrolizumab reduced the risk of disease progression or death by 52% and the risk of death by 49% compared to chemotherapy. The survival benefit was consistent regardless of cisplatin eligibility or the presence of liver metastases. The confirmed objective response rate was higher with enfortumab vedotin and pembrolizumab at 67.5% compared to 44.2% with chemotherapy. The median duration of response was 23.3 months with enfortumab vedotin and pembrolizumab compared to 7.0 months with chemotherapy. A complete response was achieved in 30.4% of patients in the enfortumab vedotin and pembrolizumab group compared to 14.5% in the chemotherapy group, with the median duration of complete response not yet reached in the enfortumab vedotin and pembrolizumab group compared to 15.2 months in the chemotherapy group. Severe treatment-related adverse events occurred in 57.3% of patients treated with enfortumab vedotin and pembrolizumab compared to 69.5% in the chemotherapy group, while in patients who achieved a complete response, severe adverse events occurred in 61.7% of those treated with enfortumab vedotin and pembrolizumab compared to 71.9% with chemotherapy. Treatment-related deaths were reported in 1.1% of patients treated with enfortumab vedotin and pembrolizumab compared to 0.9% with chemotherapy, with no treatment-related deaths occurring in those who achieved a complete response. These findings clearly confirm the durable efficacy of enfortumab vedotin and pembrolizumab, reinforcing its role as the standard of care for the first-line treatment of patients with locally advanced or metastatic urothelial carcinoma, and no new safety concerns have been identified. Dr. Neeraj Agarwal: Thank you for this great summary. Moving on to kidney cancer, let's talk about Abstract 439 titled, “Nivolumab plus cabozantinib (N+C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): Final follow-up results from the CheckMate-9ER trial.” Dr. Peter Hoskin: Sure. Dr. Motzer presented the final results from the phase 3 CheckMate-9ER trial, which compared the combination of cabozantinib and nivolumab against sunitinib in previously untreated advanced renal cell carcinoma. The data after more than five years follow-up show that the combination therapy provided sustained superior efficacy compared to sunitinib. In terms of overall survival, we see an 11-month improvement in median OS, 46.5 months for the cabo-nivo versus 35.5 months for sunitinib and a 42% reduction in the risk of disease progression or death, with median progression-free survival nearly doubling – that's 16.4 months in the combination group and 8.3 months with sunitinib. Importantly, the safety profile was consistent with the known safety profiles of the individual medicines, with no new safety concerns identified. Dr. Neeraj Agarwal: Great summary, Peter. These data further support the efficacy of cabo-nivo combination therapy in advanced renal cell carcinoma, which is showing a 11-month difference in overall survival. Dr. Peter Hoskin: Neeraj, before wrapping up this podcast, would you like to tell us about Abstract 618? This is titled “Prospective COTRIMS (Cologne trial of retroperitoneal lymphadenectomy in metastatic seminoma) trial: Final results.” Dr. Neeraj Agarwal: Sure, Peter. I would be delighted to. Dr Heidenrich from the University of Cologne in Germany presented the COTRIMS data evaluating retroperitoneal LN dissection in patients with clinical stage 2A/B seminomas. Seminomas are classified as 2A or B when the disease spreads to the retroperitoneal lymph nodes of up to 2 cm (CS IIA) or of more than 2 cm to up to 5 cm (CS 2B) in maximum diameter, respectively. They account for 10-15% of seminomas and they are usually treated with radiation and chemotherapy. However, radiation and chemo can be associated with long-term toxicities such as cardiovascular toxicities, diabetes, solid cancers, leukemia, particularly for younger patients. From this standpoint, Dr Heidenrich and colleagues evaluated unilateral, modified template, nerve-sparing retroperitoneal lymph node dissection as a less toxic alternative compared to chemo and radiation. They included 34 patients with negative AFP, beta-HCG, and clinical stage 2A/B seminomas. At a median follow-up of 43.2 months, the trial demonstrated great outcomes: a 99.3% treatment-free survival rate and 100% overall survival, with only four relapses. Antegrade ejaculation was preserved in 88% of patients, and severe complications such as grade 3 and 4 were observed in 12% of patients. Pathological analysis revealed metastatic seminoma in 85% of cases, with miR371 being true positive in 23 out of 24 cases and true negative in 100% of cases. It appears to be a valid biomarker for predicting the presence of lymph node metastases. These findings highlight retroperitoneal lymph node dissection is feasible; it has low morbidity, and excellent oncologic outcomes, avoiding overtreatment in 80% of patients and sparing unnecessary chemotherapy or radiotherapy in 10-15% of cases. Dr. Peter Hoskin: Great summary and important data on retroperitoneal lymphadenectomy in metastatic seminoma. These findings will help shape clinical practice. Any final remarks before we conclude today's podcast? Dr. Neeraj Agarwal: Before wrapping up this podcast, I would like to say that we have reviewed several abstracts addressing prostate, bladder, kidney cancers, and seminoma, which are impacting our medical practices now and in the near future. Peter, thank you for sharing your insights with us today. These updates are undoubtedly exciting for the entire GU oncology community, and we greatly appreciate your valuable contribution to the discussion and your leadership of the conference. Many thanks. Dr. Peter Hoskin: Thank you, Neeraj. Thank you for the opportunity to share this information more widely. I'm aware that whilst we have nearly 6,000 delegates, there are many other tens of thousands of colleagues around the world who need to have access to this information. And it was a great privilege to chair this ASCO GU25. So, thank you once again, Neeraj, for this opportunity to share more of this information that we discussed over those few days. Dr. Neeraj Agarwal: Thank you, Peter. And thank you to our listeners for joining us today. You will find links to the abstracts discussed today on the transcript of this episode. Finally, if you value the insights that you hear on the ASCO Daily News podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement.  Find out more about today's speakers:   Dr. Neeraj Agarwal    @neerajaiims    Dr. Peter Hoskin Follow ASCO on social media:      @ASCO on Twitter      ASCO on Bluesky  ASCO on Facebook      ASCO on LinkedIn      Disclosures: Dr. Neeraj Agarwal: Consulting or Advisory Role: Pfizer, Bristol-Myers Squibb, AstraZeneca, Nektar, Lilly, Bayer, Pharmacyclics, Foundation Medicine, Astellas Pharma, Lilly, Exelixis, AstraZeneca, Pfizer, Merck, Novartis, Eisai, Seattle Genetics, EMD Serono, Janssen Oncology, AVEO, Calithera Biosciences, MEI Pharma, Genentech, Astellas Pharma, Foundation Medicine, and Gilead Sciences Research Funding (Institution): Bayer, Bristol-Myers Squibb, Takeda, Pfizer, Exelixis, Amgen, AstraZeneca, Calithera Biosciences, Celldex, Eisai, Genentech, Immunomedics, Janssen, Merck, Lilly, Nektar, ORIC Pharmaceuticals, Crispr Therapeutics, Arvinas Dr. Peter Hoskin: Research Funding (Institution): Varian Medical Systems, Astellas Pharma, Bayer, Roche, Pfizer, Elekta, Bristol Myers  

Dave becomes acquainted with Dr. Kim Byas, who, among his several current endeavors, including Vice President of Community Engagement and Impact at The Center for Health Affairs, is a member of the Conscious Leadership Guild. In the course of this conversation, Kim introduces the concept of the origin story. Each of us has one, yet to inform and grow our practices, we can become more aware of this unique personal resource. Journaling is one way of doing so. 

Send us a textIn this captivating episode, Joey Pinz sits down with communication expert Amanda Kenderes, who unveils her groundbreaking model of three "Talk Types" that define how we interact with one another. Amanda breaks down the "A," "B," and "C" communication styles—Informing, Relating, and Meeting Makers—into a simple framework that anyone can use to better understand themselves and those around them.

Today, we're joined by Emad Mostaque, an innovative leader in the AI field and founder of Shelling AiH. In this episode, we delve deep into the intricacies of artificial intelligence, exploring its immense potential as well as the challenges and ethical dilemmas it poses. Tom and Emad discuss the critical aspects of AI control, the risk of subtle manipulation, and the importance of decentralized and open-source models. They investigate how AI can transform sectors like education, healthcare, and governance, while also addressing concerns about autonomy, transparency, and societal impacts. Join us as we navigate the philosophical and practical dimensions of AI's role in our future, examining everything from economic disruptions to the potential reshaping of democracy, and the very nature of work and human fulfillment. This discussion is packed with insights, thought-provoking questions, and forward-thinking solutions that you won't want to miss. SHOWNOTES 00:00 China's geostrategic impact more concerning than AI. 07:03 Digital control to change Hollywood employment landscape. 13:41 Talk show hosts influence public opinion, political change. 18:46 Informing citizens enhances representation in democratic processes. 24:49 Tech enables democracy, transparency; builds personal defenses. 28:42 New AI models excel in complex tasks. 33:42 Increasing compute leads to internal AI politics. 41:24 AI trust issues, governance, open-source data needed. 45:24 Computers build usable AI models for collaboration. 50:14 Open source AI systems need customizable governance. 55:52 China may use AI for invasive surveillance. 01:03:24 AI governance threatens individual privacy and control. 01:08:57 Purpose and happiness intertwine, balancing freedoms' concepts. 01:13:16 Design systems to enhance human agency, capability. 01:20:17 Coordination needed for food, education, resources globally. 01:26:34 Success is valued through personal achievement and progress. 01:28:27 Overcame illness, wrote reflective book on life. CHECK OUT OUR SPONSORS Range Rover: Explore the Range Rover Sport at  https://landroverUSA.com Oracle: Take a free test drive of OCI at https://oracle.com/theory Shopify: Sign up for your one-dollar-per-month trial period at https://shopify.com/impact Momentous: Shop now at https://livemomentous.com and use code IMPACT for 20% your new Momentous routine. FOLLOW TOM: Instagram: https://www.instagram.com/tombilyeu/ Tik Tok: https://www.tiktok.com/@tombilyeu?lang=en Twitter: https://twitter.com/tombilyeu YouTube: https://www.youtube.com/@TomBilyeu What's up, everybody? It's Tom Bilyeu here. If you're serious about leveling up your life, I urge you to check out my new podcast, Tom Bilyeu's Mindset Playbook —a goldmine of my most impactful episodes on mindset, business, and health. Trust me, your future self will thank you. LISTEN AD FREE + BONUS EPISODES on APPLE PODCASTS: apple.co/impacttheory Learn more about your ad choices. Visit megaphone.fm/adchoices